Expression of chemokines and their receptors by human brain endothelium: Implications for multiple sclerosis by Subileau, Eve A et al.
Open Research Online
The Open University’s repository of research publications
and other research outputs
Expression of chemokines and their receptors by human
brain endothelium: Implications for multiple sclerosis
Journal Item
How to cite:
Subileau, Eve A; Rezaie, Payam; Davies, Heather; Colyer, Frances; Greenwood, John; Male, David and Romero,
Ignacio A (2009). Expression of chemokines and their receptors by human brain endothelium: Implications for multiple
sclerosis. Journal of Neuropathology and Experimental Neurology, 68(3) pp. 227–240.
For guidance on citations see FAQs.
c© 2009 American Association of Neuropathologists, Inc
Version: [not recorded]
Link(s) to article on publisher’s website:
http://dx.doi.org/doi:10.1097/NEN.0b013e318197eca7
Copyright and Moral Rights for the articles on this site are retained by the individual authors and/or other copyright
owners. For more information on Open Research Online’s data policy on reuse of materials please consult the policies
page.
oro.open.ac.uk
Expression of chemokines and their receptors by human brain endothelium: 
Implications for multiple sclerosis
Eve A. SUBILEAU, PhD1; Payam REZAIE, PhD1; Heather A. Davies, MIBiol 1; Frances M. 
Colyer, FIBMS 1; John GREENWOOD, PhD2; David K. MALE, PhD1; Ignacio A. 
ROMERO, PhD1*.
1 Department of Life Sciences, The Open University, Walton Hall, Milton Keynes MK7 6AA, 
and 2 Department of Cell Biology, Institute of Ophthalmology, 11-43 Bath Street, London 
EC1V 9EL, United Kingdom.
*Corresponding author: Ignacio A. Romero, Department of Life Sciences, The Open 
University, Walton Hall, Milton Keynes MK7 6AA, United Kingdom, Tel +44 1908 659467, 
Fax +44 1908 654167, e-mail i.romero@open.ac.uk
Running title: Chemokines and receptors on human brain endothelium
Acknowledgements: We are grateful to Dr R. Selway and staff at King’s College Hospital, 
London, the UK Multiple Sclerosis Tissue Bank, and the MRC London Brain Bank for 
Neurodegenerative Diseases (Dr. Safa Al-Sarraj, Clinical Director) for provision of human 
tissues for use in our investigations. This work was supported by The Multiple Sclerosis 
Society of Great Britain and Northern Ireland.
Role of Authors: EAS carried out most of the experiments for her PhD thesis under the 
direct supervision of IAR, JG and DKM; PR carried out the analysis of chemokine expression 
in post mortem tissue sections; HAD and FMC provided technical support for the 
immunogold electron microscopy studies. The manuscript was written by EAS, PR, DKM
and IAR.
*Clean revised manuscript
Abstract
Leukocyte migration into the CNS is mediated by chemokines, expressed on the surface of 
brain endothelium. This study investigated the production of chemokines and expression of 
chemokine receptors by human brain endothelial cells (HBEC), in vitro and in situ in multiple 
sclerosis tissue. Four chemokines (CCL2, CCL5, CXCL8 and CXCL10), were demonstrated 
in endothelial cells in situ, which was reflected in the chemokine production by primary 
HBEC and a brain endothelial cell line, hCEMC/D3. CXCL8 and CCL2 were constitutively 
released and increased in response to TNF and/or IFN . CXCL10 and CCL5 were 
undetectable in resting cells but were secreted in response to these cytokines. TNF strongly 
increased the production of CCL2, CCL5 and CXCL8, while IFN up-regulated CXCL10 
exclusively. CCL3 was not secreted by HBECs and appeared to be confined to astrocytes in 
situ. The chemokine receptors CXCR1 and CXCR3 were expressed by HBEC both in vitro
and in situ, and CXCR3 was up-regulated in response to cytokine stimulation in vitro. By 
contrast, CXCR3 expression was reduced in silent MS lesions. Brain endothelium expresses 
particularly high levels of CXCL10 and CXCL8, which may account for the predominant 
TH1-type inflammatory reaction seen in chronic conditions such as multiple sclerosis. 
Keywords: Inflammation; blood-brain barrier; brain endothelium; multiple sclerosis; 
chemokines.
Introduction
Chemokines are low molecular weight chemotactic cytokines that regulate leukocyte 
trafficking into tissues and are thought to be key mediators of the inflammatory response. 
Over 40 different chemokines, binding to 18 different chemokine receptors, have been 
identified to date [1]. The position of the first and second conserved cysteine residues
determines the basis for the classification of chemokines into four families (CC, CXC, CX3C 
and XC or the and subfamilies in the old nomenclature, respectively). Many 
chemokines can bind to different receptors within the same sub-group and most receptors can 
bind to several different chemokines. This is thought to ensure the redundancy of the system 
[2]. Indeed, most of the knock-out mice for chemokines or chemokine receptors are viable 
with the exception of CXCL12 and its receptor CXCR4 [3-5].
Multiple Sclerosis (MS) is considered to be an autoimmune disorder of unknown aetiology, in 
which a strong TH1-type immune response develops in the CNS, associated with production 
of  the inflammatory cytokines interferon- (IFN, tumour necrosis factor- (TNF), and  
transforming growth factor-2 (TGF2). Activated T-lymphocytes and macrophages cross the 
blood-brain barrier (BBB) and target myelin, creating demyelinated plaques which are 
associated with areas of chronic active inflammation [6]. A range of chemokines and their 
receptors are highly expressed on infiltrating leukocytes as well as on CNS resident cells of 
MS lesions. These include CCL2, CCL3, CCL5, CCL19, CCL21 and CXCL8 and 10 and 
their cognate receptors [7-11]. Amongst these, the increased expression of CXCL10 and its 
receptor, CXCR3, has been shown to be a prominent feature of reactive astrocytes [12] and  
infiltrating CD3+ T cells within lesions [13]. This observation is important for understanding 
disease pathology because CXCL10 is an IFN-inducible chemokine and its receptor CXCR3 
is highly expressed on active IFN-producing TH1 cells. Consequently, once a TH1-type 
response has developed in the CNS, the induction of IFN-inducible chemokines will 
selectively attract further TH1 cells to the site of inflammation, thus reinforcing the chronic 
inflammation. In addition, CXCL8 expression has been shown to be increased in MS, 
although its exact role in MS pathogenesis remains unknown [14]
Of the CC chemokines, CCL2, CCL3, CCL5 and their receptors, CCR1 CCR2 and CCR5 
show increased expression in MS lesions [15] on microglia and astrocytes or on the 
infiltrating lymphocytes and macrophages. The increase of CCL2, CCL3 and CCL5 also 
occurs in experimental autoimmune encephalomyelitis (EAE), an animal model for MS [16], 
and it was thought that CCL2 signalling could be important in attracting macrophages to sites 
of neuroinflammation. This view is supported by the observation that CCL2 knock-out mice 
showed a reduced clinical EAE score [17] and knock out of its receptor CCR2 prevented mice 
from developing EAE in one study [18].  Other important CC chemokines in MS 
pathogenesis are CCL19 and CCL21 which have been shown to be involved in T 
lymphocyte migration into the CNS in EAE and MS [7].
Most studies of chemokine expression in MS or EAE have focussed on chemokine production 
by CNS parenchymal cells or infiltrated leukocytes, assuming that chemokines expressed in 
the parenchyma will be transported to the lumenal surface of the endothelium. However, the 
potential for chemokines to move to the lumen is very limited, because brain endothelia
normally have continuous tight junctions, preventing paracellular diffusion of proteins. 
Moreover, transcytosis is also limited in brain endothelium, as the cells have relatively few 
transport vesicles, by comparison with other endothelia. For these reasons, chemokine 
production by brain endothelial cells themselves may be particularly important in regulating
leukocyte traffic into the CNS (i.e. they may represent the primary source of chemokines that 
interact directly with circulating leukocytes).  As endothelia from different tissues secrete
different subsets of chemokines, it potentially has a major role in determining the 
characteristics of inflammation in each tissue [19], and this is particularly true for brain 
endothelium. 
The aim of this study was to identify the pattern of chemokine expression by human brain 
endothelium both in the resting state and in response to inflammatory cytokines. In the study, 
we used primary human brain endothelial cells (HBEC) and an immortalised human brain 
endothelial cell line hCMEC/D3 [20]. The chemokines investigated in this study included a 
subset of chemokines potentially involved in MS pathogenesis, namely CXCL8, CXCL10, 
CCL2, CCL3 and CCL5, as there is evidence that that they may be produced by vascular 
endothelium [19]. The findings in vitro were related to observations of chemokine expression 
by the endothelial cells of cerebral capillaries in situ in normal CNS and in areas of 
neuroinflammation in MS. 
In addition, the expression of chemokine receptors on brain endothelium in vitro and in situ
was investigated. The functional significance of endothelial chemokine receptors is not fully 
understood [21]. They may be involved in clearance of chemokines from the cell surface, by 
endocytosis [22-24]. It has also been proposed that they are involved in transcytosis [25, 26].
Alternatively, some chemokines have angiogenic or angiostatic properties, so the presence of 
receptors could allow these cells to respond appropriately to signals for proliferation [27]. 
Berger and colleagues [28] have previously demonstrated the expression of CXCR1, CXCR3, 
CCR2 and CCR5 by cultured human brain endothelial cells but there is little comparative data 
on cells in situ [25]. We therefore examined MS tissue using immunohistochemistry and 
immunogold labelling combined with transmission electron microscopy to identify specific 
chemokine receptors (CXCR1 and CXR3), in order to establish whether our findings in vitro
reflect the expression of the receptors in situ. By identifying the sets of chemokines and their 
distribution, the work indicates which of the chemokines present in neuroinflammation are 
localised in endothelium, where they can control leukocyte transmigration.
Materials and methods
Human brain tissue and cell culture
Human brain tissue from the frontal or temporal cortex was obtained with ethical approval,
either post-mortem from patients diagnosed clinically and neuropathologically with multiple 
sclerosis through the UK Multiple Sclerosis Tissue Bank (London), and the MRC London 
Brain Bank for Neurodegenerative Diseases (Institute of Psychiatry, London), as indicated in 
Table 1 (10 female, 3 male, mean age of 55.6 ± 4.37 years, range 34-92 years of age), or from 
three epilepsy patients undergoing temporal lobe resection (King’s College Hospital, 
London), according to local ethical committee guidelines (Protocol 99-002). Tissues obtained 
from the frontal and temporal lobes of MS patients contained demyelinated plaques and/or
non-affected (non-demyelinated) regions (Table 1). Brain tissues were used for 
immunohistochemical and electron microscopic analyses (froze, formalin-fixed and paraffin-
embedded materials) as indicated in Table 1. Fresh brain tissue was available from five cases 
(Table 1, cases 4, 5, 6, 7 and 9) for setting up primary brain endothelial cultures (from the 
non-affected white matter in two cases, from a silent lesion in one case, and from the white 
matter of two other cases in which lesion activity had not been determined at post-mortem).
Primary human brain endothelial cells were isolated according to previously described 
techniques [29], with the modification that cells were cultured in medium containing 0.5 
g/ml puromycin for 5 days to remove contaminating cells [30]. For isolating primary HBEC, 
1 cm3 tissue blocks were required in order to obtain sufficient capillaries to generate pure 
endothelial cultures. In MS brain tissue, the blocks were taken from areas that contained MS 
lesions (as determined by naked eye) but that also contained periplaque areas and surrounding 
NAWM. HBEC reached confluence 2-3 weeks post-isolation and were used between 
passages 2 and 4. Purity was confirmed by staining for Von Willebrand factor. HBEC and the 
hCMEC/D3 cell line [20], were cultured in EBM-2 (Cambrex, Wokingham, UK)
supplemented with VEGF, IGF, bFGF, hydrocortisone, ascorbate, gentamycin and 2.5 % fetal 
bovine serum (FBS), but were rested in the same medium without growth factors for at least 
48 hours before assay.
Typing of lesions in MS brain tissue samples
Lesions within the white matter in MS tissues were characterised according to (i) classical 
histological labelling with luxol fast blue, (ii) immunostaining with myelin-associated 
proteins (myelin basic protein and proteolipid protein) (neuropathological samples), and/or 
(iii) immunostaining patterns for CD68 and MHC class II antigens [31]. Active 
(demyelinating) lesions are hypercellular and can be characterised by infiltrating MHC-II 
positive macrophages throughout the lesions; chronic active lesions are demyelinated with 
hypocellular centers, but are hypercellular at the periphery, with  activated macrophages 
located primarily at the edge of the lesion and chronic inactive or ‘silent’ lesions are 
hypocellular and lack MHC-II positive cells [31]. 
Sectioned materials were taken to methanol/hydrogen peroxide solution, permeabilised with 
0.1% triton X100 in PBS for 1 h, and non-specific binding sites were blocked using 10% 
normal rabbit serum for 1 h. The primary antibodies (CD68, clone PGM1, 1/20 and MHC 
class II, clone CR3/43, from DakoCytomation, UK) were incubated on the slide overnight at 
RT, and processed according to established immunoperoxidase protocols (Dako 3-step ABC-
HRP protocol, DakoCytomation, UK), using 1:100 biotinylated rabbit anti-mouse IgG as 
secondary antibody. In the sampled tissues, ‘active’ lesions were identified by the abundance 
of CD68 positive/MHC class II positive mononuclear phagocytes within a lesion core;
‘chronic active’ lesions as CD68 positive/MHC class II positive primarily at the edge of the 
lesion, and CD68 positive/MHC class II negative within the centre; ‘silent’ lesions were 
CD68 negative/MHC class II negative [31] (suppl. Fig. 1). A total of 13-16 active/chronic 
active lesions from five cases, and silent lesions from six cases (Table 1) were investigated 
for chemokine and chemokine receptor expression in situ.
Immunoperoxidase staining of chemokines in situ
The immunoperoxidase staining procedure for chemokines and chemokine receptors in situ
(tissue samples) was performed as previously described [32] with minor modifications. 
Formalin-fixed and fresh-frozen tissue blocks were sectioned serially at 10/20 m thickness 
using a cryostat, and collected on superfrost plus slides. Frozen sections were air-dried for 90 
minutes RT, immersed in methanol containing 2.5% of a 30% hydrogen peroxide solution, 
incubated in Hanks Balanced Saline Solution (HBSS) containing 1% bovine serum albumin, 
1% of a [1M] stock of MgCl2 and CaCl2, and 0.01% Tween 20. Sections were next incubated 
with 10% appropriate normal sera (rabbit, or swine) made up in phosphate buffered saline 
solution (PBS) for 90 minutes, prior to incubation with primary antibody solution for 24-36 
hours at 4oC (1/500, 1/100 or 1/100 dilutions of mouse monoclonal IgG1 antibodies for 
CXCL8, CCL2 and CCL3, respectively; 1/1000 or 1/500 dilution of rabbit polyclonal IgG 
antibodies for CXCL10 and CCL5, respectively; PeproTech, London, UK). Negative controls 
were included, where the primary antibody step was omitted and sections incubated with 
normal sera alone. Following three 5-minute washes in PBS, sections were incubated in 
relevant biotinylated secondary antibodies (rabbit anti-mouse IgG, 1:100; swine anti-rabbit 
IgG, 1:100, DakoCytomation Ltd., UK) for 120 minutes, washed in three changes of PBS and 
incubated with Avidin-Biotin-Horseradish Peroxidase Complex (ABC-HRP Standard Kit, 
Vector Laboratories, UK) made up according to the manufacturer’s instructions, for a further 
90-120 minutes. After a final three washes in PBS, the sections were reacted with 0.5mg/ml 
3,3'-Diaminobenzidine (DAB) made up in PBS to which 20 l of hydrogen peroxide was 
added, and the reaction timed for optimal staining (3-5 minutes). Nuclei were weakly 
counterstained with Harris’ Haematoxylin solution if required, and sections differentiated in 
0.1% acid alcohol solution (10 sec) before being rinsed under running tap water. Sections 
were then dehydrated in a graded series of alcohol (50%, the 75%, 90%, 95%, and 100% 
ethanol), cleared in xylene, and coverslipped using DPX mountant (VWR Ltd., Dorset, UK). 
Slides were viewed using a brightfield microscope. Formalin-fixed, paraffin-embedded tissue 
blocks were also sectioned at 3m using a base-sledge microtome, dewaxed in xylene and 
transferred to 100% alcohol, before immersion in methanol/hydrogen peroxide solution and 
immunohistochemical staining as described above. 
Immunofluorescence labelling of chemokine receptors in situ and in culture
For chemokine receptor staining, fresh tissues were also fixed using 2% para-formaldehyde 
(PAF) and 3.75% acrolein in 0.1M PB for 1 h and left overnight in 2% PAF only. The 
sections were cut at 50m using a Vibratome (Leica Microsystems, Milton Keynes, UK). For 
immunolabelling to detect vWF/GFAP and CXCR1/CXCR3, an antigen retrieval step was 
included, by incubating for 20 min in 0.01M citrate buffer, pH 6, at 95ºC. All sections were 
then permeabilized with 0.1% triton X100 in PBS for 1 h. Non-specific binding was blocked 
using 10% normal goat serum for 1 h. Sections were incubated with mouse anti-
CXCR1/CXCR3 (10g/ml, R&D, Oxon, UK) or their respective isotype-matched antibody 
controls for 1 h, and after 3 washes, followed by Cy3-conjugated goat anti-mouse IgG (1/100, 
Chemicon, Hampshire, UK). Sections were then incubated with a rabbit polyclonal anti-
human vWF (1/800, Sigma, Dorset, UK) or anti-GFAP (1/100, Chemicon, Hampshire, UK) 
antibodies in PBS overnight at RT, and detected using goat anti-rabbit-Ig conjugated to FITC 
(1/200, Chemicon, Hampshire, UK), incubated for 1 h. Sections were mounted using Mowiol. 
Negative controls were included, where sections were incubated with normal sera in place of 
primary antibodies.
For characterisation of chemokine/ receptor expression in vitro, cultured endothelial cells 
were first grown to 50 % confluence on collagen-coated Labtek multiwell chambered slides 
(Nunc, Scientific Laboratory Supplies, Nottingham, UK), and fixed using 4% 
paraformaldehyde in PBS for 10 min. The cells were permeabilised using 0.1 % triton X-100 
in PBS for 5 min. Non-specific binding sites were then blocked using 10% normal goat serum 
in PBS for 1 h, followed by 1 h incubation with primary  antibodies at room temperature. 
Chemokine receptor expression was determined using a panel of phycoerythrin or 
fluorescein-conjugated mouse monoclonal antibodies specific for CCR1, CCR2, CCR5, 
CXCR1, CXCR2 and CXCR3 (R&D systems, Oxon, UK) or their respective isotype-matched 
antibody controls as previously described (15). These were applied for 1 h at RT at the 
recommended dilutions. After 3 washes, the slides were mounted with a glass coverslip with 
Dako Fluorescent Mounting Medium (DakoCytomation Ltd, Cambridgeshire, UK) and 
viewed with a fluorescence microscope (Olympus BX61).
Immunogold labelling and electron microscopy
For chemokine receptor staining, fresh tissue was fixed using 2% p-formaldehyde and 3.75% 
acrolein in 0.1M phosphate buffer (PB) for 1 h and left overnight in 2% p-formaldehyde. The 
sections were cut at 50m using a vibratome. The floating sections were treated with 1% 
sodium borohydride in PB for 30 min and then freeze-thawed to permeabilise the tissue. The 
sections were incubated in Cryoprotectant solution and then rapidly immersed in 
chloriduofluromethane, followed by liquid nitrogen and then in three successive PB washes. 
Blocking solution was added for 30 min, and sections were incubated with primary mouse 
antibody (mouse IgG2A anti-human CXCR1, 5g/ml or mouse IgG1 anti-human CXCR3, 
1g/ml, R&D, Oxon, UK) or their respective isotype-matched antibody controls for 24 h at 
RT and a further 24 h at 4ºC in 0.1%BSA in TS. Non specific binding of the secondary 
antibody was blocked with the incubation/washing buffer for 10 min after a rinse with PBS. 
Sections were then incubated for 2 h with goat anti-mouse IgG secondary antibody (dilution 
1/50) conjugated to colloidal gold (British Biocell International, Cardiff, UK) in the 
incubation/washing buffer. After a 5 min wash with the incubation/washing buffer and three 
rinses with PBS, bound (1 nm) gold particles were fixed using 2% glutaraldehyde in PBS for 
10 min followed by a wash in a 0.2M citrate buffer solution. The sections were reacted with a 
silver enhancement solution (British Biocell International, Cardiff, UK). The silver 
enhancement reaction was stopped by two washes in the citrate buffer and three washes with 
PB. The immunogold stained tissue was post-fixed for 1 h in 2% osmium tetroxide in PB for 
electron microscopic viewing. They were then dehydrated in a series of ethanol  solutions 
(concentration 50%, 70%, 80%, 95% for 5 min, and twice in 100% for 10 min) and twice in 
propylene oxide for 10 min before being embedded in Epon 812 between sheets of Aclar 
plastic. Epon polymerisation was carried out by incubation at 60°C over 48 h, and a sample of 
the tissue was mounted on the tips of Epon Block. Ultra-thin sections of 70 nm were cut with 
a diamond knife (Diatone, TAAB, Gillingham, UK) and collected on copper mesh grids. The 
sections on grids were counterstained with uranyl acetate for 20 min and lead citrate for 6 
min, and examined with a Joel JEM1010 electron microscope attached to a Gatan Bioscan 
digital camera (Joel, Welwyn Garden City, UK). Micrographs at X8000 magnifications were 
taken, scanned with Epson perfection 4870 photo, and visualised with Photoshop 5.5 
programme. For quantification of the density area (number of gold particles/m2), the 
negative film of the photograph was scanned and used to count the number of gold particles 
within endothelial cells. The surface of the endothelial cells was determined from the digital 
images, using NIH image programme on a Macintosh G4.The subcellular localisation of gold 
particles in the cells was recorded as cytoplasmic, luminal or abluminal.
RT-PCR
RNA was isolated from primary HBEC grown to confluence in a 25cm2 flask coated with 
collagen. Total RNA was extracted using 1 ml of TRIzol LS (Invitrogen, Paisley, UK) 
according to the manufacturer’s protocol and stored at -80 °C. For the reverse transcription 
(RT) procedure, the protocol given by the supplier, Promega (ImProm-IITM Reverse 
transcriptase) was followed. Briefly, 2 g of RNA was mixed with 1 g of random primers at 
70ºC for 5 min then annealed on ice. Reverse transcriptase was carried out by addition of 40 
ml RT mix at 25ºC for 5 min followed by 60 min at 40 ºC. To terminate the reaction, the mix 
was incubated for a further 15 min at 70 ºC. The negative control for each sample consisted of 
RNA samples annealed with random primers without the Reverse Transcriptase. The resulting 
cDNA was either stored at -20ºC, or taken directly into the PCR amplification procedure.
The PCR amplification steps were performed by adding 4 l of cDNA from the RT reaction 
to 20 l of PCR mix (50mM KCl, 10mM Tris-HCl, pH 9.0 at 25°C, and 0.1% Triton® X-
100), 1.5mM MgCl2, 0.2mM of dNTPs, 1M of each primer and 1U of Taq polymerase) and 
placed into an iCycler PCR machine (Bio-Rad Laboratories, Hertfordshire, UK). PCR 
conditions were 5 min at 94C, followed by 40 cycles (94ºC, 45 s; Ta indicated below, 45 s, 
72ºC, 60 s) finishing at 72ºC for 7 min. Primers, Ta and size of PCR product were as follows: 
CCR1, F5’ACGAAAGCCTACGAGAGTG3’, R5’GGTGAACAGGAAGTCTTGG3’, Ta 50 
ºC, 240 bp; CCR2 F5’GATTACGGTGCTCCCTGTC3’, 
R5’GCCACAGACATAAACAGAATC3’, Ta 50, 496 bp; CCR5, 
F5’GCTGAGACATCCGTTCCCCTACA3’, R5’GGTGACCGTCCTGGCTTTTA3’, Ta 58
ºC, 477 bp; CXCR1 F5’GTGATGCTGGTCATCTTATACAG3’,
R5’TTGTTTGGATGGTAAGCCTGG3’, Ta 52 ºC, 230 bp; CXCR2 
F5’CGAAGGACCGTCTACTCATC3’, R5’AGTGTGCCCTGAAGAAGAGC3’, Ta 53 ºC, 
519 bp; CXCR3 F5’GGAGCTGCTCAGAGTAAATCAC3’, 
R5’GCACGAGTCACTCTCGTTTTC3’, Ta 53 ºC, 200 bp. Each sample was run in parallel 
with cyclophilin primers, acting as a positive control [33]. PCR products were visualized 
using agarose gel electrophoresis.
Capture ELISA
Primary HBEC (passage 2) were cultured on collagen-coated 24 well plates until confluent
and treated for 48 h with cytokines at the following concentrations: TGF- at 25ng/ml, TNF
at 25ng/ml and IFN at 100ng/ml (R&D Systems, Oxon, UK). Culture supernatants were then 
collected and frozen at -20ºC until further analysis. Chemokines were measured by sandwich 
ELISA (R&D systems, Oxon, UK), according to the manufacturer’s protocols. The standard 
range for all four chemokines tested was between 0.03 and 8 ng/ml. Only absorbance values 
within the linear part of the standard curve corresponding to supernatants and/or diluted 
supernatants were used for each experiment. For experiments on polarized secretion of 
chemokines, transwell polyester membrane inserts [Corning Costar, UK (0.4 µm pore, 12mm 
diameter)] were first coated with rat collagen [Sigma-Aldrich, UK, (0.005 % w/v, 1 h at room 
temperature)]and then with human fibronectin [Sigma-Aldrich, UK (5 μg/ml, 1 h)]. Primary 
HBEC cells were grown to confluence (~ 1 x 105 cells/cm2) with a culture media change 
every 2-3 days and incubated for 2 days post confluence prior to treatment.
Flow Cytometry
Chemokine receptor expression on hCMEC/D3 cells in the absence or presence of cytokines 
(25ng/ml TNF and 100ng/ml IFN for 24 h) was determined using a panel of fluorescently 
labelled antibodies (R&D Systems, Oxon, UK) as previously described [33]. Briefly, 
hCMEC/D3 cells were grown to confluence, washed and trypsinized using 0.25% 
trypsin/EDTA (Invitrogen, UK). Cells were fixed using 1ml 4% p-formaldehyde in PBS for 
10 min at 4oC and then centrifuged at 300xg for 5 min. Cells were then permeabilised using 
0.1% Triton-X-100 in PBS for 1 min at room temperature, centrifuged at 300xg for 5 min, 
resuspended in 1 ml of blocking solution (0.1 mg/ml human IgG /10% normal goat serum in 
PBS), and incubated for 30 min at 4oC. Cells were counted and resuspended at 8·106 cells/ml.  
For the assay, 25l of the cell suspension (2·105 cells) was added 10l of appropriate 
antibodies at the manufacturer’s recommended concentrations. Appropriate isotype-matched 
controls were used. Cells were incubated with antibodies for 1 h at 4oC, then washed once 
using PBS and resuspended in 0.4 ml PBS for analysis.  Flow cytometry data was acquired 
and analysed using the FACScalibur flow cytometer and CellQuestTM software (Becton 
Dickinson, UK).
Statistical analysis
Significance was determined by a one way or two way ANOVA, followed by a post hoc 
Tukeys t-test. P<0.05 was considered significant. For CXCL8 production by HBEC, the data 
were not normally distributed and a Kruskal-Wallis and Mann-Whitney test was used.
Results
Expression of chemokines by human cerebral endothelium in multiple sclerosis
Endothelial cells in non-demyelinated, normal-appearing white matter (NAWM) and cortical 
grey matter showed a vesicular staining for CCL2 (MCP-1: Fig. 1A) and CXCL8 (IL-8: Fig. 
1H). Higher power magnification shown in Figs. 1A' and 1A'' illustrate this expression more 
clearly for CCL2. These chemokines as well as CCL3 (MIP-1), CCL5 (RANTES) and 
CXCL10 (IP-10) were detected on the surface of endothelial cells and/or on surrounding cells 
but there were differences in the pattern of expression between normal and plaque tissue. 
While CCL2 heavily stained endothelial cells in large vessels and surrounding cells within the 
demyelinated plaque (Fig. 1C), expression in adjacent non-affected cortical areas (white and 
grey matter) was more patchy on the vasculature, and was sometimes associated with 
perivascular cells (Fig. 1B, asterisk). The localisation of CXCL8 closely matched that 
described for CCL2 within the plaque area (Fig. 1I) and in adjacent non-affected regions (not 
shown). Similarly, CCL5 showed a finely-peppered, patchy distribution at the surface of 
endothelial cells (Fig. 1F). By contrast, CCL3 staining in the plaques was primarily detected 
on fine processes radiating perpendicularly away from the blood vessels (Fig. 1D). This 
pattern of immunoreactivity can be seen to a much lesser extent on endothelial cells of blood 
vessels in non-affected areas (Fig. 1E). The pattern of staining for CCL3 suggests that it is 
primarily associated with astrocyte processes and end-feet rather than the endothelium or 
other perivascular cells. CXCL10 is more diffusely expressed on vascular endothelium in the 
demyelinating plaque (Fig. 1G),. These results implicate human brain endothelial cells as a
source of chemokines in vivo, both in the resting state (CCL2, CXCL8) and in inflammation
(CCL2, CCL5, CXCL8, CXCL10).
Chemokine secretion by primary human brain endothelial cells and hCMEC/D3 cells
In order to determine whether human brain endothelial cells can secrete chemokines, the 
chemokine levels constitutively released into the culture medium by cultured primary human 
brain endothelial cells (HBEC) isolated from 5 MS donors and 3 epileptic donors and by the 
hCMEC/D3 cell line were determined by ELISA (Fig. 2). Out of the five chemokines tested 
only CCL2 and CXCL8 were constitutively produced by all cells tested. This finding 
corroborates the observation that only these two chemokines are present in the NAWM in 
situ. Basal CCL2 levels released by primary HBEC from MS brain tissue in the range 1.4 -
22.7 ng/ml (n=5), was similar to that produced by HBEC from temporal lobe resected tissue 
(4.4 - 14.3 ng/ml (n=3)). CXCL8 constitutive levels were more variable as primary HBEC 
from MS brain tissue ranged to from 3.2 - 206 ng/ml (n=5) and HBEC from epileptic 
temporal lobe tissue which ranged from 45 - 142 ng/ml (n=3). Endothelium from both 
sources may be considered ‘resting’, since they had been removed from potential micro-
environmental proinflammatory stimuli for at least one week in vitro before assay.
Following cytokine stimulation, chemokine release into the culture medium increased to 
similar levels from primary HBEC of both MS brain tissue and temporal lobe resections (Fig. 
2). However, specific cytokines or combinations of cytokines differentially affected
chemokine secretion. The most potent activator of CXCL8 and CCL2 production by primary 
HBEC was TNF alone, although the effect of TNF on CXCL8 secretion was effectively 
blocked by co-incubation with either IFN or TGF. Both CXCL10 and CCL5 were 
maximally induced by IFN in combination with TNF although in the case of CXCL10, 
IFN alone was sufficient to induce a considerable increase in CXCL10 production. CCL3 
was not released into the culture medium either basally or following any of the conditions 
tested (data not shown), correlating with the results in situ, where CCL3 appeared to be
associated with astrocytes rather than endothelium.  
The hCMEC/D3 cell line, largely exhibited the same pattern of chemokine secretion as 
primary HBEC with two exceptions: 1) the basal levels of CCL2 and CXCL8 secretion was 
lower than those observed for primary HBEC and 2) TNF alone was sufficient to induce 
CXCL10 synthesis (Fig. 2).
Since chemokines are presented to circulating leukocytes, we investigated whether primary 
HBEC cells grown on filters were polarized in their secretion either constitutively or
following stimulation with TNF and IFN. Constitutive CCL2 and CXCL8 levels were 
similar in both the upper and lower chambers (Fig.3). By contrast, following stimulation with 
TNF and IFNγ, the concentrations of all chemokines were higher in the upper than in the 
lower chamber although increased apical levels were statistically significant only for CCL2, 
CXCL8 and CXCL10 (Fig.3). These results indicate that cytokine-induced chemokine 
secretion was preferentially directed to the apical side of the endothelium.  
Chemokine receptor expression by cultured human brain endothelial cells
It is possible that chemokines released into the circulation act on brain endothelial cells in an 
autocrine manner or that receptors are involved in clearance of free chemokines from plasma. 
We therefore investigated the expression by cultured brain endothelial cells of the chemokine 
receptors to which the chemokines investigated above bind, namely CXCR1-3 and CCR1, 2 
and 5. Using semi-quantitative RT-PCR, primary HBEC expressed CCR1, CCR5 and 
CXCR1-3 mRNA but not CCR2 (Fig. 4a). At the protein level, CXCR1 and 3 were present at 
high levels, whereas levels of CXCR2 and CCR5 were lower and CCR1 and 2 were not 
detected by immunocytochemistry (Fig. 4b).  CXCR1 and CXCR3 appeared to be localised 
mainly intracellularly, in particular around the nucleus. The pattern of chemokine receptor 
expression did not differ between cells originating from MS brains and those obtained from 
epileptic patients (data not shown). 
The pattern of chemokine receptor expression of primary HBEC was similar to that observed 
in the hCMEC/D3 cell line, with CXCR1 and CXCR3 showing the highest levels of 
expression amongst the chemokine receptors tested (16). We therefore used this cell line to 
quantify changes in chemokine receptor expression induced by cytokines using FACScan 
analysis. Following incubation of hCMEC/D3 with TNF and IFN for 24 h, only CXCR3 
expression was significantly increased (p<0.05, n=3) whereas CCR1 expression was induced 
(p<0.05, n=3). No changes in expression were observed for CXCR1, CXCR2, CCR2 or
CCR5 (Fig. 5). 
Chemokine receptor expression by human brain endothelium in situ
Since CXCR1 and CXCR3 appeared to be expressed at high levels by cultured HBEC and 
CXCR3 was upregulated by cytokine stimulation, a detailed analysis of the expression of 
these two chemokine receptors by HBEC was performed in situ in MS brain sections. Active 
(CD68+, MHC class II+) and silent (CD68+, MHC class II -) lesions were compared with 
normal appearing white matter (NAWM) (CD68-, MHC class II-) in terms of expression of 
CXCR1 and CXCR3 by immunohistochemistry. In 50 m sections, double labelling with von 
Willebrand factor, an endothelial marker, and either CXCR1 or CXCR3 (Fig. 6a) revealed 
chemokine receptor staining associated with blood vessels in NAWM. In addition, other cells 
within the brain parenchyma which were negative for von Willebrand factor were also 
positively labelled for CXCR1 and CXCR3. Since human astrocytes have been previously 
shown to express CXCR1 and CXCR3 (29), double labelling with either CXCR1 or CXCR3 
and GFAP, a specific marker for astrocytes, was carried out to determine whether the positive 
chemokine receptor expression by blood vessels was due to associated astrocytic end-feet. A 
clear co-localisation of CXCR1 (Fig. 6b) and CXCR3 (not shown) with GFAP was observed 
in the astrocytic processes surrounding blood vessels. In addition, cells enclosed within the 
astrocytic end-feet were also positively labelled for CXCR1 (Fig. 6b) and CXCR3 (not
shown), although whether these cells were endothelial cells could not be ascertained. In MS 
lesions, CXCR1 (not shown) and CXCR3 (Fig. 6c) positive staining was diffuse throughout 
the lesion, probably due to astrogliosis and/or leukocyte infiltration.
Subcellular localisation of CXCR1 and CXCR3 by immunogold labelling and electron 
microscopy
To determine whether endothelial cells expressed chemokine receptors in situ, the 
immunogold technique using monoclonal antibodies to CXCR1 and CXCR3 was carried out 
on sections of MS brain tissue. Immunogold labelling with the monoclonal CXCR1 and 
CXCR3 antibodies revealed gold particles along the plasma membrane and cytoplasm of the 
endothelial cells, pericytes and astrocytic end-feet (Fig. 7a,b,d). Leukocytes, whether 
infiltrated or interacting with the endothelial cells on the luminal side, were also labelled for 
CXCR1 (Fig. 7c) and, to a lesser extent, CXCR3 (not shown). 
In the context of endothelial cells, labelling was easily identified at both the lumenal and 
ablumenal plasma membranes and within the cytoplasm of the capillary endothelial cells (Fig. 
7d). The total number of gold particles on endothelial cells per surface area for CXCR1 and 
CXCR3 did not vary significantly between NAWM, active lesions and silent lesions, with the 
exception of CXCR3 in silent lesions which was significantly lower than in NAWM or active 
lesions (Table 2). In NAWM, CXCR1 and CXCR3 antigenic sites were mainly localized at 
the cytoplasm, in particular for CXCR1 with approximately 87% of gold particles located in 
the cytoplasm compared to 65% for CXCR3 (Table 2). The distribution of antigenic sites 
between the lumenal and ablumenal membranes was different for CXCR1 and CXCR3, with 
a higher percentage of gold particles on the lumenal membrane compared to the ablumenal 
membrane for CXCR1, whereas the opposite was observed for CXCR3 (Table 2). The 
endothelial subcellular distribution of CXCR1 in MHC class II+ (active) and MHC class II-
(silent) lesions did not differ significantly from that observed in NAWM. By contrast, a 
significant reduction in CXCR3-immunolabelling on the lumenal membrane and a significant 
increase in CXCR3-immunolabelling within the cytoplasm was detected in MHC class II+
lesions (Table 2). Control experiments carried out to assess labelling specificity showed a 
negligible number of gold particles randomly distributed when the primary antibody was 
omitted.
Discussion
Many chemokines are strongly expressed in the CNS during multiple sclerosis [11]. However, 
it is thought that the set of chemokines which are expressed on the lumenal surface of the 
endothelium controls the pattern of leukocyte migration into each tissue including the CNS. 
Chemokines may be synthesised by the endothelium [19] or produced within tissues and 
transported across the endothelium in transport vesicles including caveolae [22, 26].
Transcytosis is more likely to be important in tissues such as the lung, where the bulk 
transport systems are well developed [34]. Conversely, in the brain, where the endothelial 
barrier is strong and transcytosis limited, chemokine secretion by the endothelium itself is 
likely to be more important. Endothelia from different tissues vary in their chemokine 
secretion profiles and the rate of chemokine clearance from the cell surface [35]. Moreover,
chemokine binding to the cell surface depends on the glycocalyx: brain microvascular 
endothelium has a particularly high negative charge, due to its sulphated gycosaminoglycans, 
which can interact with and retain positively-charged chemokines [36]. For these reasons, 
identifying chemokine production by brain endothelium is particularly important for 
understanding the distinctive patterns of leukocyte migration that occur in the CNS.
This study has shown that CCL2 and CXCL8 are produced and secreted by resting brain 
endothelium in vitro and by cerebral endothelium in normal-appearing brain tissue in situ. 
These chemokines, together with CXCL10 and CCL5 are induced following activation by 
inflammatory cytokines in endothelial cells in vitro, and in areas of inflammation and 
demyelination in MS tissue. Chemokine production by brain endothelium is indeed distinct 
from other endothelial subtypes, including primary microvascular endothelium from lung, 
dermis and liver and saphenous vein endothelium [19]. Our results are in agreement with 
previous reports demonstrating production of CCL2 and CXCL8 by HBEC isolated from 
temporal lobe of epileptic patients under resting conditions [37] and following stimulation 
with cytokines [38] or with supernatants derived from allogeneic or myelin basic protein 
reactive TH1 cells [39]. In this study, the chemokine profiles from primary brain endothelium
were similar, regardless of whether the cells came from MS patients or temporal lobe 
resection, and were broadly similar to the results with the cell line hCMEC/D3, suggesting 
that, in MS, HBEC do not show increased chemokine production per se but rather respond 
normally to the inflammatory environment they are exposed to by releasing chemokines. 
However, the level of production of CXCL8 and CXCL10 by brain endothelium is high by 
comparison with non-brain endothelia [19]. The finding with CXCL10 is notable, since this 
chemokine acts on CXCR3, which is strongly expressed on activated TH1 cells, precisely the 
population that is thought to drive the neuropathology of MS.
In contrast to other chemokines, CXCL8 secretion by HBEC was more variable either in 
resting or cytokine-stimulated cells. However, both EP and MS HBEC appeared to secrete 
variable levels of CXCL8 depending on the individual donor rather that on tissue type. This 
variability in CXCL8 expression has been observed by others in response to the HIV-1 
protein tat [40] and in endothelial cells from non-CNS tissues in response to cytokines [19]. It 
is possible that the number of cell divisions is a critical factor regulating the storage of 
CXCL8 in non-brain endothelial cells, as previously demonstrated  [41]..In primary cultures, 
the number of cell divisions at the time of the assay could have varied between donors as the 
yield of capillary fragments and hence the number of cell divisions to attain confluence is 
dependent on a number of factors (post-mortem time, quantity of tissue, cause of death, 
among others). Another possibility involves inter-individual variation amongst different 
donors. Indeed, CXCL8 plasma levels of healthy blood donors varied greatly in a recent study 
[42] and variablity has also been demonstrated between different ethnic groups [43].
The downregulatory effect of IFN and TGF on the TNF-induced upregulation of CXCL8 
secretion merits attention. Indeed, TGFis considered to be an anti-inflammatory cytokine 
and its expression has been detected in active MS lesions [44]. However, CXCL8 inhibition 
by TGFwas only partial suggesting that it may not exert its anti-inflammatory effects in the 
presence of high levels of pro-inflammatory cytokines. The inhibitory effect of IFN on 
TNF-induced CXCL8 production has been reported in other cell types such as monocytes 
[45]. The activation of NFB and AP-1 by TNF, required for CXCL8 transcription, is 
inhibited in the presence of IFN in endothelial cells [46]. The suppression of CXCL8 
production by IFN may thus be considered a protective effect against CXCL-8 mediated 
neutrophil infiltration. Another important finding from the present study is that brain 
endothelium does not produce CCL3 in vitro. This is consistent with the observations in situ, 
which suggest that astrocytes, rather than endothelium are the main source of CCL3. These 
results stress the importance of correlating in vitro and in situ studies when investigating MS 
pathogenesis.
How does chemokine expression by HBEC relate to leukocyte infiltration? Apical release of 
chemokines by brain endothelium in vitro may rather reflect the rapid dilution of this 
chemokine by the blood stream in vivo. Indeed, chemokines released in the circulation would 
be rapidly degraded by proteases or their actions neutralized by decoy chemokine receptors 
such as DARC expressed by erythrocytes [47]. Alternatively, chemokines released by 
endothelial cells may bind to the endothelial glycocalyx either on the secretory cell itself or 
on other endothelial cells further along the capillary wall trapping immune cells within the 
inflamed area either at the lumen or within the perivascular space. This may apply to 
CXCL10, as high levels of its receptor, which might serve to bind this chemokine, are 
detected on the abluminal side of brain endothelial cells in situ. Indeed, previous studies stress 
the importance of chemokines in directing leukocyte trafficking into the CNS. In chronic 
relapsing EAE in mice, disease severity correlated with CCL3 production during the initial 
acute phase, but more closely with CCL2 levels during relapse [48]. These observations and 
the fact that CCL2-null mice do not develop EAE indicate a potential role for CCL2 in the 
development of neuroinflammation [18]. Whether CCL2 is essential in EAE has however 
been questioned by other studies which show that EAE can develop in a number of CCR2-
deficienct mice [49]. In this model  neuropathological examination showed a higher 
proportion of neutrophils and fewer macrophages than in normal animals, which suggests that 
macrophages can be partly replaced by neutrophils in producing the EAE pathology although 
it still implies that CCL2/CCR2 are important in monocyte migration into the CNS. In 
multiple sclerosis the levels of CCL3 in the CSF have a weak positive relationship to the level 
of cells present [50] but this may merely reflect the fact that inflammation will activate 
astrocytes to produce CCL3, and does not necessarily imply that CCL3 is required to drive 
leukocyte transmigration. Indeed other evidence suggests that CCL2 is also important in 
controlling monocyte migration in MS and that migrating cells lose their CCR2 receptor as 
they transmigrate [10]. 
There is also considerable evidence that at least some endothelial-derived chemokines 
regulate leukocyte trafficking into the CNS, specifically of TH1 cells. Supernatants from 
TH1, but not TH2, cells induce production of CXCL10, CXCL8 and CCL2 by HBEC [39]. 
Using an in vitro human BBB model, Prat et al. [37] demonstrated that antibody 
neutralization of CCL2 considerably reduced migration of T lymphocytes isolated from MS 
patients across HBEC. Indeed, CCL2 has been shown to be crucial for the TH1 immune 
response in EAE [17]. These studies were expanded to show, using intravital microscopy, that 
treatment with anti-CCL2 or anti-CCL5 antibodies prevent leukocyte adhesion, but not 
rolling, in EAE [51]. Our results have shown that brain endothelium itself is a major source of 
CCL2 as well as CXCL10, both of which have been implicated in the development of TH1-
type inflammatory reactions in MS.
The expression of chemokine receptors on brain endothelium as determined by fluorescence 
microscopy and FACS analysis shows some similarity to other endothelia, with high 
expression of CXCR1 and CXCR3. Our findings are generally in agreement with Berger et al 
[28] who showed expression of CXCR1-3 by HBEC, although the expression of CXCR2 was 
low in the present study. In addition, we confirmed a low expression of CCR5 in agreement 
with other in vitro [28, 52] and in situ [53] studies. By contrast, although CCR2 expression 
has previously been reported in HBEC [28], and more recently also in mouse BEC at the 
protein and mRNA level [54], we could not demonstrate CCR2 expression either at the 
protein or transcript level in our study. Species differences in CCR2 expression cannot be 
ruled out at present. In the study of Berger et al [28], HBEC were positive by 
immunofluorescence using goat polyclonal antibodies to CCR2A but not with those to 
CCR2B, whereas we used a more specific CCR2 monoclonal antibody. In addition, 
Andjelkovic et al [52] showed binding sites to CCL2 in isolated human brain capillaries, 
although this may either be due to other cell types expressing CCR2 such as perivascular 
cells/pericytes, or to other endothelial chemokine receptors (i.e. DARC).
The function of endothelial chemokine receptors has not been defined. Interestingly, CXCR1 
and CXCR3 bind to CXCL8 and CXCL10 respectively, which would allow secreted 
chemokines to act in an autocrine fashion. Previous studies have suggested that signalling via 
CXCR1 is angiogenic, whereas signalling via CXCR3 is angiostatic [27]. Another potential 
function for endothelial chemokine receptors is to clear the plasma of free chemokines, so that 
leukocytes do not become activated unless they are triggered by chemokines held on the 
endothelial glycocalyx. Finally, it has been proposed that chemokine receptors could be 
involved in transport of chemokines across endothelium. Our observation that the subcellular 
localization of CXCR3 is altered in MS lesions compared to NAWM is suggestive of this 
hypothesis. Indeed, there appears to be an increase in the intracellular pool of CXCR3, and a 
decrease in the ablumenal membrane in MS lesions. The fact that CXCL10 induces the 
internalisation of its receptor [55] might account for the observed increase in the intracellular 
pool of CXCR3 as CXCL10 is increased in MS lesions and could explain the decrease of the 
receptor on the ablumenal side. CCR2 has been suggested to act as a means of transport for its 
chemokine ligand, CCL2 across the BBB [56]. It is possible that the same case applies for 
CXCR3 and its ligand, as they are greatly increased in the lesions, mainly in the active 
lesions. Indeed, we have shown that CXCR3 is upregulated by cytokine treatment in a human 
brain endothelial cell line. However, our in vitro results should be approached with caution as 
hCMEC/D3 cells do no retain all characteristics of the BBB phenotype, such as high 
transendothelial resistance [20], and the pattern of chemokine expression was somewhat 
different between primary HBEC and the immortalised cell line. Whether CXCR3 transports 
CXCL10 across human brain endothelium remains to be determined. 
This study has shown that human brain endothelium cultured in vitro expresses a similar 
pattern of chemokines and chemokine receptors to that seen in situ. It has shown that brain 
endothelium responds to cytokine stimulation by secreting chemokines, and does so with the 
same response pattern as other microvascular endothelium. However it also highlights the 
high secretion of CXCL8 and CXCL10, in comparison with other endothelia, which may
explain the distinctive TH1-pattern of chronic inflammation in the brain, seen in diseases such 
as MS. 
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Figure legends
Fig. 1: Chemokine expression in multiple sclerosis brain tissue 
Representative photographs taken from sections of the frontal lobe of cases with MS (Table 
1) immunolabelled to detect CCL2, CCL5, CXCL8 or CXCL10 .  [A, A', A'', H]: paraffin-
embedded sections at 3m thickness. [B-G, I]: frozen sections cut at 20m thickness [A, A', 
A'',B, H] are taken from non-demyelinated areas. [C-G, I] are taken from demyelinating 
plaque areas.  [A'] and [A''] represent high power photographs of endothelial cells expressing 
CCL2 from the same case as shown in [A].  [A' and A''] show higher power photographs of 
endothelial cells expressing CCL2. Polarised expression is indicated by an arrowhead in [A']. 
The (unlabelled) nucleus of an endothelial cell is indicated by the adjacent (e) in [A'']. The 
asterisk in [B] denotes a perivascular cell expressing CCL2, associated with the external 
(parenchymal) blood vessel wall. The scale bar represents approx. 115m in [A], 20m in 
[A', A''], 195m in [B], 410m in [C], 150m in [D], 95m in [E,F], 85m in [G], 100m in 
[H] and 335m in [I]. Nuclei have not been counterstained.
Fig. 2: Chemokine release into culture medium by primary HBEC and the hCMEC/D3 
cell line under basal conditions and following stimulation by cytokines for 48 h.
Supernatants from confluent monolayers of HBEC or hCMEC/D3 cells were collected after 
48 h stimulation with TNF (50 ng/ml), IFN (100 ng/ml) and TGF (25 ng/ml) or a 
combination of them and assayed by sandwich ELISA for (a) CXCL8 (b) CXCL10 (c) CCL2 
and (d) CCL5. Results presented are means ± S.E.M. of 3-5 different experiments for HBEC 
isolated from MS brain tissue (white), 3 for HBEC isolated from temporal lobe resections 
from epileptic patients (grey) and 3 for the hCMEC/D3 cell line (black) with duplicate wells. 
Significant differences were determined by ANOVA followed by a post hoc t-test for CCL2, 
CCL5 and CXCL10 and by a Kruskal-Wallis and Mann-Whitney test for CXCL8. * 
significant difference (p<0.05) versus the control; Δ significant difference (p<0.05) of sample 
treated with a combination of cytokines versus TNF- treated sample;  significant difference 
(p<0.05) of sample treated with a combination of cytokines versus IFN treated sample.
Fig 3: Chemokine release into the apical and baso-lateral culture medium by primary 
HBEC grown on filters under basal conditions and following stimulation by cytokines. 
Supernatants from confluent monolayers of human brain endothelial cells grown on filters 
were collected at 48 h from both the apical (white) and the basolateral sides (grey) and 
assayed by sandwich ELISA for CXCL8, CXCL10, CCL2, and CCL5. Results presented are 
means ± S.D. from two different experiments with duplicate wells. Significant differences 
were determined by ANOVA followed by a post hoc t-test. * significant difference (p<0.05) 
versus the control;  significant difference (p<0.05) between concentration at the apical 
chamber and the basal chamber.
Fig. 4. Chemokine receptor expression by primary HBEC detected by (a) semi-
quantitative RT-PCR and (b) immunocytochemistry. cDNA for CCR1, CCR5, CXCR1, 
CXCR2 and CXCR3 was detected in primary HBEC but not that of CCR2 (+). Cyclophilin 
was used as positive control and to ensure equal cDNA loading for each sample. Negative 
controls (-) of samples incubated in the absence of RT were included. Results are 
representative of 2 experiments. (b) Immunofluorescence staining of primary HBEC for 
CCR5, CXCR1, CXCR2 and CXCR3 (Texas red; bottom). CXCR1 and CXCR3 showed a 
predominant surface staining extending over the cell body. CXCR2 and CCR5 showed 
predominantly vesicle staining. Scalebar = 20 m.
Fig. 5. Chemokine receptor expression by hCMEC/D3 cells under basal conditions and 
following stimulation by cytokines for 24 h.  (a) Representative FACScan histograms show 
the expression of unstimulated hCMEC/D3 cells (black line) and hCMEC/D3 cells stimulated 
with 500ng/ml TNFα and 10ng/ml IFN for 24 h (grey line). hCMEC/D3 cells were fixed 
with 4% PAF, permeabilised with triton X-100, labelled with FITC- or PE- labelled 
antibodies specific for CXCR1, CXCR2, CXCR3, CCR1, CCR2 and CCR5, and analysed by 
FAScan. Cells labelled with FITC- or PE- labelled isotope-matched antibodies are 
represented as grey filled histograms. The histograms are of one experiment representative of 
three. (b) Results are expressed as the mean fluorescence for chemokine receptor expression 
by unstimulated hCMEC/D3 cells (white) and hCMEC/D3 cells stimulated with 500ng/ml 
TNFα and 10ng/ml IFNγ (grey) for 24 h. Control values have been subtracted. Significance 
was tested on normalised values by ANOVA with a post hoc t-test (* p<0.05). Results 
presented are the mean ± S.E.M. of three different experiments. 
Fig. 6. Immunofluorescent detection of CXCR1 and CXCR3 in human NAWM and MS 
lesions. Fixed 50 m thick sections cut with a vibratome were permeabilised with triton X-
100 and then processed for detection of either CXCR1 (b) or CXCR3 (a, c) (in red) and either 
von Willebrand factor (a), an endothelial cell marker, or GFAP (b,c), an astrocyte marker, (in 
green) by immunohistochemistry in NAWM (a, b) and in a chronic active MS lesion (c). 
Merged images show the localisation of CXCR1 and CXCR3 within the neurovascular unit. 
Results are representative of experiments from six donors. Scale bar= 40 m
Fig. 7. Electron micrographs of CXCR1 and CXCR3-labelled MS brain tissue. Fixed 50 
m thick sections were processed for detection of CXCR1 and CXCR3 using silver-enhanced 
gold particles and visualized by electron microscopy. (A) Brain capillary endothelial cells and 
the perivascular end-feet of astrocytes show CXCR1-antigenic sites positively labelled with 
gold particles in NAWM. (B) In a chronic active lesion (MHC class II +), both brain capillary 
endothelial cells and pericytes are labelled for CXCR1. Inset represents dashed area at higher
magnification showing positive immunogold labelling for CXCR1 on the lumenal surface of 
brain endothelial cells. (C) Leukocytes interacting with brain endothelial cells within the 
lumen (asterisk) are highly positive for CXCR1 in a chronic active lesion (MHC class II +). 
(D) In a silent lesion, CXCR3 is distributed mainly within the cytoplasm of endothelial cells 
(some within endosomes) but also on the lumenal (asterisk) and ablumenal membranes. 
Abbreviations: AE=astrocytic end-feet; EC= endothelial cell; E= erythrocyte; L=leukocyte; 
P=pericyte. Scale bar= 1 m
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Abstract
Leukocyte migration into the CNS is mediated by chemokines, expressed on the surface of 
brain endothelium. This study investigated the production of chemokines and expression of 
chemokine receptors by human brain endothelial cells (HBEC), in vitro and in situ in multiple 
sclerosis tissue. Four chemokines (CCL2, CCL5, CXCL8 and CXCL10), were demonstrated 
in endothelial cells in situ, which was reflected in the chemokine production by primary 
HBEC and a brain endothelial cell line, hCEMC/D3. CXCL8 and CCL2 were constitutively 
released and increased in response to TNF and/or IFN . CXCL10 and CCL5 were 
undetectable in resting cells but were secreted in response to these cytokines. TNF strongly 
increased the production of CCL2, CCL5 and CXCL8, while IFN up-regulated CXCL10 
exclusively. CCL3 was not secreted by HBECs and appeared to be confined to astrocytes in 
situ. The chemokine receptors CXCR1 and CXCR3 were expressed by HBEC both in vitro
and in situ, and CXCR3 was up-regulated in response to cytokine stimulation in vitro. By 
contrast, CXCR3 expression was reduced in silent MS lesions. Brain endothelium expresses 
particularly high levels of CXCL10 and CXCL8, which may account for the predominant 
TH1-type inflammatory reaction seen in chronic conditions such as multiple sclerosis. 
Keywords: Inflammation; blood-brain barrier; brain endothelium; multiple sclerosis; 
chemokines.
Introduction
Chemokines are low molecular weight chemotactic cytokines that regulate leukocyte 
trafficking into tissues and are thought to be key mediators of the inflammatory response. 
Over 40 different chemokines, binding to 18 different chemokine receptors, have been 
identified to date [1]. The position of the first and second conserved cysteine residues
determines the basis for the classification of chemokines into four families (CC, CXC, CX3C 
and XC or the and subfamilies in the old nomenclature, respectively). Many 
chemokines can bind to different receptors within the same sub-group and most receptors can 
bind to several different chemokines. This is thought to ensure the redundancy of the system 
[2]. Indeed, most of the knock-out mice for chemokines or chemokine receptors are viable 
with the exception of CXCL12 and its receptor CXCR4 [3-5].
Multiple Sclerosis (MS) is considered to be an autoimmune disorder of unknown aetiology, in 
which a strong TH1-type immune response develops in the CNS, associated with production 
of  the inflammatory cytokines interferon- (IFN, tumour necrosis factor- (TNF), and  
transforming growth factor-2 (TGF2). Activated T-lymphocytes and macrophages cross the 
blood-brain barrier (BBB) and target myelin, creating demyelinated plaques which are 
associated with areas of chronic active inflammation [6]. A range of chemokines and their 
receptors are highly expressed on infiltrating leukocytes as well as on CNS resident cells of 
MS lesions. These include CCL2, CCL3, CCL5, CCL19, CCL21 and CXCL8 and 10 and 
their cognate receptors [7-11]. Amongst these, the increased expression of CXCL10 and its 
receptor, CXCR3, has been shown to be a prominent feature of reactive astrocytes [12] and  
infiltrating CD3+ T cells within lesions [13]. This observation is important for understanding 
disease pathology because CXCL10 is an IFN-inducible chemokine and its receptor CXCR3 
is highly expressed on active IFN-producing TH1 cells. Consequently, once a TH1-type 
response has developed in the CNS, the induction of IFN-inducible chemokines will 
selectively attract further TH1 cells to the site of inflammation, thus reinforcing the chronic 
inflammation. In addition, CXCL8 expression has been shown to be increased in MS, 
although its exact role in MS pathogenesis remains unknown [14]
Of the CC chemokines, CCL2, CCL3, CCL5 and their receptors, CCR1 CCR2 and CCR5 
show increased expression in MS lesions [15] on microglia and astrocytes or on the 
infiltrating lymphocytes and macrophages. The increase of CCL2, CCL3 and CCL5 also 
occurs in experimental autoimmune encephalomyelitis (EAE), an animal model for MS [16], 
and it was thought that CCL2 signalling could be important in attracting macrophages to sites 
of neuroinflammation. This view is supported by the observation that CCL2 knock-out mice 
showed a reduced clinical EAE score [17] and knock out of its receptor CCR2 prevented mice 
from developing EAE in one study [18].  Other important CC chemokines in MS 
pathogenesis are CCL19 and CCL21 which have been shown to be involved in T 
lymphocyte migration into the CNS in EAE and MS [7].
Most studies of chemokine expression in MS or EAE have focussed on chemokine production 
by CNS parenchymal cells or infiltrated leukocytes, assuming that chemokines expressed in 
the parenchyma will be transported to the lumenal surface of the endothelium. However, the 
potential for chemokines to move to the lumen is very limited, because brain endothelia
normally have continuous tight junctions, preventing paracellular diffusion of proteins. 
Moreover, transcytosis is also limited in brain endothelium, as the cells have relatively few 
transport vesicles, by comparison with other endothelia. For these reasons, chemokine 
production by brain endothelial cells themselves may be particularly important in regulating
leukocyte traffic into the CNS (i.e. they may represent the primary source of chemokines that 
interact directly with circulating leukocytes).  As endothelia from different tissues secrete
different subsets of chemokines, it potentially has a major role in determining the 
characteristics of inflammation in each tissue [19], and this is particularly true for brain 
endothelium. 
The aim of this study was to identify the pattern of chemokine expression by human brain 
endothelium both in the resting state and in response to inflammatory cytokines. In the study, 
we used primary human brain endothelial cells (HBEC) and an immortalised human brain 
endothelial cell line hCMEC/D3 [20]. The chemokines investigated in this study included a 
subset of chemokines potentially involved in MS pathogenesis, namely CXCL8, CXCL10, 
CCL2, CCL3 and CCL5, as there is evidence that that they may be produced by vascular 
endothelium [19]. The findings in vitro were related to observations of chemokine expression 
by the endothelial cells of cerebral capillaries in situ in normal CNS and in areas of 
neuroinflammation in MS. 
In addition, the expression of chemokine receptors on brain endothelium in vitro and in situ
was investigated. The functional significance of endothelial chemokine receptors is not fully 
understood [21]. They may be involved in clearance of chemokines from the cell surface, by 
endocytosis [22-24]. It has also been proposed that they are involved in transcytosis [25, 26].
Alternatively, some chemokines have angiogenic or angiostatic properties, so the presence of 
receptors could allow these cells to respond appropriately to signals for proliferation [27]. 
Berger and colleagues [28] have previously demonstrated the expression of CXCR1, CXCR3, 
CCR2 and CCR5 by cultured human brain endothelial cells but there is little comparative data 
on cells in situ [25]. We therefore examined MS tissue using immunohistochemistry and 
immunogold labelling combined with transmission electron microscopy to identify specific 
chemokine receptors (CXCR1 and CXR3), in order to establish whether our findings in vitro
reflect the expression of the receptors in situ. By identifying the sets of chemokines and their 
distribution, the work indicates which of the chemokines present in neuroinflammation are 
localised in endothelium, where they can control leukocyte transmigration.
Materials and methods
Human brain tissue and cell culture
Human brain tissue from the frontal or temporal cortex was obtained with ethical approval,
either post-mortem from patients diagnosed clinically and neuropathologically with multiple 
sclerosis through the UK Multiple Sclerosis Tissue Bank (London), and the MRC London 
Brain Bank for Neurodegenerative Diseases (Institute of Psychiatry, London), as indicated in 
Table 1 (10 female, 3 male, mean age of 55.6 ± 4.37 years, range 34-92 years of age), or from 
three epilepsy patients undergoing temporal lobe resection (King’s College Hospital, 
London), according to local ethical committee guidelines (Protocol 99-002). Tissues obtained 
from the frontal and temporal lobes of MS patients contained both demyelinated plaques 
and/or non-affected (non-demyelinated) regions (Table 1). Brain tissues were used for 
immunohistochemical and electron microscopic analyses (froze, formalin-fixed and paraffin-
embedded materials) as indicated in Table 1. Fresh brain tissue was available from five cases 
(Table 1, cases 4, 5, 6, 7 and 9) for setting up primary brain endothelial cultures (from the 
non-affected white matter in two cases, from a silent lesion in one case, and from the white 
matter of two other cases in which lesion activity had not been determined at post-
mortem).isolating cerebral endothelial cells and astrocytes (fresh material) or for 
immunohistochemical and electron microscopic analyses (frozen, formalin-fixed and paraffin-
embedded materials) (see Table 1).
Primary human brain endothelial cells were isolated according to previously described 
techniques [29], with the modification that cells were cultured in medium containing 0.5 
g/ml puromycin for 5 days to remove contaminating cells [30]. For isolating primary HBEC, 
1 cm3 tissue blocks were required in order to obtain sufficient capillaries to generate pure 
endothelial cultures. In MS brain tissue, the blocks were taken from areas that contained MS 
lesions (as determined by naked eye) but that also contained periplaque areas and surrounding 
NAWM. HBEC reached confluence 2-3 weeks post-isolation and were used between 
passages 2 and 4. Purity was confirmed by staining for Von Willebrand factor. HBEC and the 
hCMEC/D3 cell line [20], were cultured in EBM-2 (Cambrex, Wokingham, UK)
supplemented with VEGF, IGF, bFGF, hydrocortisone, ascorbate, gentamycin and 2.5 % fetal 
bovine serum (FBS), but were rested in the same medium without growth factors for at least 
48 hours before assay.
Typing of lesions in MS brain tissue samples
Lesions within the white matter in MS tissues were characterised according to (i) classical 
histological labelling with luxol fast blue, (ii) immunolabelling immunostaining with myelin-
associated proteins (myelin basic protein and proteolipid protein) (neuropathological 
samples), and/or (iii) immunolabelling immunostaining patterns for CD68 and MHC class II 
antigens [31]. Active (demyelinating) lesions are hypercellular and can be characterised by 
infiltrating MHC-II positive macrophages throughout the lesions but no demyelination; 
chronic active lesions are demyelinated with hypocellular centers, but are hypercellular at the 
periphery, with activated macrophages located primarily at the edge of the lesion and chronic 
inactive or ‘silent’ lesions are hypocellular and lack MHC-II positive cells [31]. 
Sectioned materials were taken to methanol/hydrogen peroxide solution, permeabilised with 
0.1% triton X100 in PBS for 1 h, and non-specific binding sites were blocked using 10% 
normal rabbit serum for 1 h. The primary antibodies (CD68, clone PGM1, 1/20 and MHC 
class II, clone CR3/43, from DakoCytomation, UK) were incubated on the slide overnight at 
RT, and processed according to established immunoperoxidase protocols (Dako 3-step ABC-
HRP protocol, DakoCytomation, UK), using 1:100 biotinylated rabbit anti-mouse IgG as 
secondary antibody. In the sampled tissues, ‘active’ lesions were identified by the abundance 
of CD68 positive/MHC class II positive mononuclear phagocytes within a lesion core (in the 
absence of significant demyelination); ‘chronic active’ lesions as CD68 positive/MHC class II 
positive primarily at the edge of the lesion, and CD68 positive/MHC class II negative within 
the centre; ‘silent’ lesions were CD68 negative/MHC class II negative [31] (suppl. Fig. 1). A 
total of 13-16 active/chronic active lesions from five cases, and silent lesions from six cases 
(Table 1) were investigated for chemokine and chemokine receptor expression in situ.
Immunoperoxidase labelling staining of chemokines in situ
The immunoperoxidase labelling staining procedure for chemokines and chemokine receptors 
in situ (tissue samples) was performed as previously described [32] with minor modifications. 
Formalin-fixed and fresh-frozen tissue blocks were sectioned serially at 10/20 m thickness 
using a cryostat, and collected on superfrost plus slides. Frozen sections were air-dried for 90 
minutes RT, immersed in methanol containing 2.5% of a 30% hydrogen peroxide solution, 
incubated in Hanks Balanced Saline Solution (HBSS) containing 1% bovine serum albumin, 
1% of a [1M] stock of MgCl2 and CaCl2, and 0.01% Tween 20. Sections were next incubated 
with 10% appropriate normal sera (rabbit, or swine) made up in phosphate buffered saline 
solution (PBS) for 90 minutes, prior to incubation with primary antibody solution for 24-36 
hours at 4oC (1/500, 1/100 or 1/100 dilutions of mouse monoclonal IgG1 antibodies for 
CXCL8, CCL2 and CCL3, respectively; 1/1000 or 1/500 dilution of rabbit polyclonal IgG 
antibodies for CXCL10 and CCL5, respectively; PeproTech, London, UK). Negative controls 
were included, where the primary antibody step was omitted and sections incubated with 
normal sera alone. Following three 5-minute washes in PBS, sections were incubated in 
relevant biotinylated secondary antibodies (rabbit anti-mouse IgG, 1:100; swine anti-rabbit 
IgG, 1:100, DakoCytomation Ltd., UK) for 120 minutes, washed in three changes of PBS and 
incubated with Avidin-Biotin-Horseradish Peroxidase Complex (ABC-HRP Standard Kit, 
Vector Laboratories, UK) made up according to the manufacturer’s instructions, for a further 
90-120 minutes. After a final three washes in PBS, the sections were reacted with 0.5mg/ml 
3,3'-Diaminobenzidine (DAB) made up in PBS to which 20 l of hydrogen peroxide was 
added, and the reaction timed for optimal staining (3-5 minutes). Nuclei were weakly 
counterstained with Harris’ Haematoxylin solution if required, and sections differentiated in 
0.1% acid alcohol solution (10 sec) before being rinsed under running tap water. Sections 
were then dehydrated in a graded series of alcohol (50%, the 75%, 90%, 95%, and 100% 
ethanol), cleared in xylene, and coverslipped using DPX mountant (VWR Ltd., Dorset, UK). 
Slides were viewed using a brightfield microscope. Formalin-fixed, paraffin-embedded tissue 
blocks were also sectioned at 3m using a base-sledge microtome, dewaxed in xylene and 
transferred to 100% alcohol, before immersion in methanol/hydrogen peroxide solution and 
immunohistochemical labelling staining as described above. 
Immunofluorescence labelling of chemokine receptors in situ and in culture
For chemokine receptor staining, fresh tissues were also fixed using 2% para-formaldehyde 
(PAF) and 3.75% acrolein in 0.1M PB for 1 h and left overnight in 2% PAF only. The 
sections were cut at 50m using a Vibratome (Leica Microsystems, Milton Keynes, UK). For 
immunolabelling to detect vWF/GFAP and CXCR1/CXCR3, an antigen retrieval step was 
included, by incubating for 20 min in 0.01M citrate buffer, pH 6, at 95ºC. All sections were 
then permeabilized with 0.1% triton X100 in PBS for 1 h. Non-specific binding was blocked 
using 10% normal goat serum for 1 h. Sections were incubated with mouse anti-
CXCR1/CXCR3 (10g/ml, R&D, Oxon, UK) or their respective isotype-matched antibody 
controls for 1 h, and after 3 washes, followed by Cy3-conjugated goat anti-mouse IgG (1/100, 
Chemicon, Hampshire, UK). Sections were then incubated with a rabbit polyclonal anti-
human vWF (1/800, Sigma, Dorset, UK) or anti-GFAP (1/100, Chemicon, Hampshire, UK) 
antibodies in PBS overnight at RT, and detected using goat anti-rabbit-Ig conjugated to FITC 
(1/200, Chemicon, Hampshire, UK), incubated for 1 h. Sections were mounted using Mowiol. 
Negative controls were included, where sections were incubated with normal sera in place of 
primary antibodies.
For characterisation of chemokine/ receptor expression in vitro, cultured endothelial cells 
were first grown to 50 % confluence on collagen-coated Labtek multiwell chambered slides 
(Nunc, Scientific Laboratory Supplies, Nottingham, UK), and fixed using 4% 
paraformaldehyde in PBS for 10 min. The cells were permeabilised using 0.1 % triton X-100 
in PBS for 5 min. Non-specific binding sites were then blocked using 10% normal goat serum 
in PBS for 1 h, followed by 1 h incubation with primary  antibodies at room temperature. 
Chemokine receptor expression was determined using a panel of phycoerythrin or 
fluorescein-conjugated mouse monoclonal antibodies specific for CCR1, CCR2, CCR5, 
CXCR1, CXCR2 and CXCR3 (R&D systems, Oxon, UK) or their respective isotype-matched 
antibody controls as previously described (15). These were applied for 1 h at RT at the 
recommended dilutions. After 3 washes, the slides were mounted with a glass coverslip with 
Dako Fluorescent Mounting Medium (DakoCytomation Ltd, Cambridgeshire, UK) and 
viewed with a fluorescence microscope (Olympus BX61).
Immunogold labelling and electron microscopy
For chemokine receptor staining, fresh tissue was fixed using 2% p-formaldehyde and 3.75% 
acrolein in 0.1M phosphate buffer (PB) for 1 h and left overnight in 2% p-formaldehyde. The 
sections were cut at 50m using a vibratome. The floating sections were treated with 1% 
sodium borohydride in PB for 30 min and then freeze-thawed to permeabilise the tissue. The 
sections were incubated in Cryoprotectant solution and then rapidly immersed in 
chloriduofluromethane, followed by liquid nitrogen and then in three successive PB washes. 
Blocking solution was added for 30 min, and sections were incubated with primary mouse 
antibody (mouse IgG2A anti-human CXCR1, 5g/ml or mouse IgG1 anti-human CXCR3, 
1g/ml, R&D, Oxon, UK) or their respective isotype-matched antibody controls for 24 h at 
RT and a further 24 h at 4ºC in 0.1%BSA in TS. Non specific binding of the secondary 
antibody was blocked with the incubation/washing buffer for 10 min after a rinse with PBS. 
Sections were then incubated for 2 h with goat anti- mouse IgG secondary antibody (dilution 
1/50) conjugated to colloidal gold (British Biocell International, Cardiff, UK) in the 
incubation/washing buffer. After a 5 min wash with the incubation/washing buffer and three 
rinses with PBS, bound (1 nm) gold particles were fixed using 2% glutaraldehyde in PBS for 
10 min followed by a wash in a 0.2M citrate buffer solution. The sections were reacted with a 
silver enhancement solution (British Biocell International, Cardiff, UK). The silver 
enhancement reaction was stopped by two washes in the citrate buffer and three washes with 
PB. The immunogold stained tissue was post-fixed for 1 h in 2% osmium tetroxide in PB for 
electron microscopic viewing. They were then dehydrated in a series of ethanol  solutions 
(concentration 50%, 70%, 80%, 95% for 5 min, and twice in 100% for 10 min) and twice in 
propylene oxide for 10 min before being embedded in Epon 812 between sheets of Aclar 
plastic. Epon polymerisation was carried out by incubation at 60°C over 48 h, and a sample of 
the tissue was mounted on the tips of Epon Block. Ultra-thin sections of 70 nm were cut with 
a diamond knife (Diatone, TAAB, Gillingham, UK) and collected on copper mesh grids. The 
sections on grids were counterstained with uranyl acetate for 20 min and lead citrate for 6 
min, and examined with a Joel JEM1010 electron microscope attached to a Gatan Bioscan 
digital camera (Joel, Welwyn Garden City, UK). Micrographs at X8000 magnifications were 
taken, scanned with Epson perfection 4870 photo, and visualised with Photoshop 5.5 
programme. For quantification of the density area (number of gold particles/m2), the 
negative film of the photograph was scanned and used to count the number of gold particles 
within endothelial cells. The surface of the endothelial cells was determined from the digital 
images, using NIH image programme on a Macintosh G4.The subcellular localisation of gold 
particles in the cells was recorded as cytoplasmic, luminal or abluminal.
RT-PCR
RNA was isolated from primary HBEC grown to confluence in a 25cm2 flask coated with 
collagen. Total RNA was extracted using 1 ml of TRIzol LS (Invitrogen, Paisley, UK) 
according to the manufacturer’s protocol and stored at -80 °C. For the reverse transcription 
(RT) procedure, the protocol given by the supplier, Promega (ImProm-IITM Reverse 
transcriptase) was followed. Briefly, 2 g of RNA was mixed with 1 g of random primers at 
70ºC for 5 min then annealed on ice. Reverse transcriptase was carried out by addition of 40 
ml RT mix at 25ºC for 5 min followed by 60 min at 40 ºC. To terminate the reaction, the mix 
was incubated for a further 15 min at 70 ºC. The negative control for each sample consisted of 
RNA samples annealed with random primers without the Reverse Transcriptase. The resulting 
cDNA was either stored at -20ºC, or taken directly into the PCR amplification procedure.
The PCR amplification steps were performed by adding 4 l of cDNA from the RT reaction 
to 20 l of PCR mix (50mM KCl, 10mM Tris-HCl, pH 9.0 at 25°C, and 0.1% Triton® X-
100), 1.5mM MgCl2, 0.2mM of dNTPs, 1M of each primer and 1U of Taq polymerase) and 
placed into an iCycler PCR machine (Bio-Rad Laboratories, Hertfordshire, UK). PCR 
conditions were 5 min at 94C, followed by 40 cycles (94ºC, 45 s; Ta indicated below, 45 s, 
72ºC, 60 s) finishing at 72ºC for 7 min. Primers, Ta and size of PCR product were as follows: 
CCR1, F5’ACGAAAGCCTACGAGAGTG3’, R5’GGTGAACAGGAAGTCTTGG3’, Ta 50 
ºC, 240 bp; CCR2 F5’GATTACGGTGCTCCCTGTC3’, 
R5’GCCACAGACATAAACAGAATC3’, Ta 50, 496 bp; CCR5, 
F5’GCTGAGACATCCGTTCCCCTACA3’, R5’GGTGACCGTCCTGGCTTTTA3’, Ta 58
ºC, 477 bp; CXCR1 F5’GTGATGCTGGTCATCTTATACAG3’,
R5’TTGTTTGGATGGTAAGCCTGG3’, Ta 52 ºC, 230 bp; CXCR2 
F5’CGAAGGACCGTCTACTCATC3’, R5’AGTGTGCCCTGAAGAAGAGC3’, Ta 53 ºC, 
519 bp; CXCR3 F5’GGAGCTGCTCAGAGTAAATCAC3’, 
R5’GCACGAGTCACTCTCGTTTTC3’, Ta 53 ºC, 200 bp. Each sample was run in parallel 
with cyclophilin primers, acting as a positive control [33]. PCR products were visualized 
using agarose gel electrophoresis.
Capture ELISA
Primary HBEC (passage 2) were cultured on collagen-coated 24 well plates until confluent
and treated for 48 h with cytokines at the following concentrations: TGF- at 25ng/ml, TNF
at 25ng/ml and IFN at 100ng/ml (R&D Systems, Oxon, UK). Culture supernatants were then 
collected and frozen at -20ºC until further analysis. Chemokines were measured by sandwich 
ELISA (R&D systems, Oxon, UK), according to the manufacturer’s protocols. The standard 
range for all four chemokines tested was between 0.03 and 8 ng/ml. Only absorbance values 
within the linear part of the standard curve corresponding to supernatants and/or diluted 
supernatants were used for each experiment. For experiments on polarized secretion of 
chemokines, transwell polyester membrane inserts [Corning Costar, UK (0.4 µm pore, 12mm 
diameter)] were first coated with rat collagen [Sigma-Aldrich, UK, (0.005 % w/v, 1 h at room 
temperature)]and then with human fibronectin [Sigma-Aldrich, UK (5 μg/ml, 1 h)]. Primary 
HBEC cells were grown to confluence (~ 1 x 105 cells/cm2) with a culture media change 
every 2-3 days and incubated for 2 days post confluence prior to treatment.
Flow Cytometry
Chemokine receptor expression on hCMEC/D3 cells in the absence or presence of cytokines 
(25ng/ml TNF and 100ng/ml IFN for 24 h) was determined using a panel of fluorescently 
labelled antibodies (R&D Systems, Oxon, UK) as previously described [33]. Briefly, 
hCMEC/D3 cells were grown to confluence, washed and trypsinized using 0.25% 
trypsin/EDTA (Invitrogen, UK). Cells were fixed using 1ml 4% p-formaldehyde in PBS for 
10 min at 4oC and then centrifuged at 300xg for 5 min. Cells were then permeabilised using 
0.1% Triton-X-100 in PBS for 1 min at room temperature, centrifuged at 300xg for 5 min, 
resuspended in 1 ml of blocking solution (0.1 mg/ml human IgG /10% normal goat serum in 
PBS), and incubated for 30 min at 4oC. Cells were counted and resuspended at 8·106 cells/ml.  
For the assay, 25l of the cell suspension (2·105 cells) was added 10l of appropriate 
antibodies at the manufacturer’s recommended concentrations. Appropriate isotype-matched 
controls were used. Cells were incubated with antibodies for 1 h at 4oC, then washed once 
using PBS and resuspended in 0.4 ml PBS for analysis.  Flow cytometry data was acquired 
and analysed using the FACScalibur flow cytometer and CellQuestTM software (Becton 
Dickinson, UK).
Statistical analysis
Significance was determined by a one way or two way ANOVA, followed by a post hoc 
Tukeys t-test. P<0.05 was considered significant. For CXCL8 production by HBEC, the data 
were not normally distributed and a Kruskal-Wallis and Mann-Whitney test was used.
Results
Expression of chemokines by human cerebral endothelium in multiple sclerosis
Endothelial cells in non-demyelinated, normal-appearing white matter (NAWM) and cortical 
grey matter showed a vesicular staining for CCL2 (MCP-1: Fig. 1A) and CXCL8 (IL-8: Fig. 
1H). Higher power magnification shown in Figs. 1A' and 1A'' illustrate this expression more 
clearly for CCL2. These chemokines as well as CCL3 (MIP-1), CCL5 (RANTES) and 
CXCL10 (IP-10) were detected on the surface of endothelial cells and/or on surrounding cells 
but there were differences in the pattern of expression between normal and plaque tissue. 
While CCL2 heavily stained endothelial cells in large vessels and surrounding cells within the 
demyelinated plaque (Fig. 1C), expression in adjacent non-affected cortical areas (white and 
grey matter) was more patchy on the vasculature, and was sometimes associated with 
perivascular cells (Fig. 1B, asterisk). The localisation of CXCL8 closely matched that 
described for CCL2 within the plaque area (Fig. 1I) and in adjacent non-affected regions (not 
shown). Similarly, CCL5 showed a finely-peppered, patchy distribution at the surface of 
endothelial cells (Fig. 1F). By contrast, CCL3 staining in the plaques was primarily detected 
on fine processes radiating perpendicularly away from the blood vessels (Fig. 1D). This 
pattern of immunoreactivity can be seen to a much lesser extent on endothelial cells of blood 
vessels in non-affected areas (Fig. 1E). The pattern of staining for CCL3 suggests that it is 
primarily associated with astrocyte processes and end-feet rather than the endothelium or 
other perivascular cells. CXCL10 is more diffusely expressed on vascular endothelium in the 
demyelinating plaque (Fig. 1G),. These results implicate human brain endothelial cells as a
source of chemokines in vivo, both in the resting state (CCL2, CXCL8) and in inflammation
(CCL2, CCL5, CXCL8, CXCL10).
Chemokine secretion by primary human brain endothelial cells and hCMEC/D3 cells
In order to determine whether human brain endothelial cells can secrete chemokines, the 
chemokine levels constitutively released into the culture medium by cultured primary human 
brain endothelial cells (HBEC) isolated from 5 MS donors and 3 epileptic donors and by the 
hCMEC/D3 cell line were determined by ELISA (Fig. 2). Out of the five chemokines tested 
only CCL2 and CXCL8 were constitutively produced by all cells tested. This finding 
corroborates the observation that only these two chemokines are present in the NAWM in 
situ. Basal CCL2 levels released by primary HBEC from MS brain tissue in the range 1.4 -
22.7 ng/ml (n=5), was similar to that produced by HBEC from temporal lobe resected tissue 
(4.4 - 14.3 ng/ml (n=3)). CXCL8 constitutive levels were more variable as primary HBEC 
from MS brain tissue ranged to from 3.2 - 206 ng/ml (n=5) and HBEC from epileptic 
temporal lobe tissue which ranged from 45 - 142 ng/ml (n=3). Endothelium from both 
sources may be considered ‘resting’, since they had been removed from potential micro-
environmental proinflammatory stimuli for at least one week in vitro before assay.
Following cytokine stimulation, chemokine release into the culture medium increased to 
similar levels from primary HBEC of both MS brain tissue and temporal lobe resections (Fig. 
2). However, specific cytokines or combinations of cytokines differentially affected
chemokine secretion. The most potent activator of CXCL8 and CCL2 production by primary 
HBEC was TNF alone, although the effect of TNF on CXCL8 secretion was effectively 
blocked by co-incubation with either IFN or TGF. Both CXCL10 and CCL5 were 
maximally induced by IFN in combination with TNF although in the case of CXCL10, 
IFN alone was sufficient to induce a considerable increase in CXCL10 production. CCL3 
was not released into the culture medium either basally or following any of the conditions 
tested (data not shown), correlating with the results in situ, where CCL3 appeared to be
associated with astrocytes rather than endothelium.  
The hCMEC/D3 cell line, largely exhibited the same pattern of chemokine secretion as 
primary HBEC with two exceptions: 1) the basal levels of CCL2 and CXCL8 secretion was 
lower than those observed for primary HBEC and 2) TNF alone was sufficient to induce 
CXCL10 synthesis (Fig. 2).
Since chemokines are presented to circulating leukocytes, we investigated whether primary 
HBEC cells grown on filters were polarized in their secretion either constitutively or
following stimulation with TNF and IFN. Constitutive CCL2 and CXCL8 levels were 
similar in both the upper and lower chambers (Fig.3). By contrast, following stimulation with 
TNF and IFNγ, the concentrations of all chemokines were higher in the upper than in the 
lower chamber although increased apical levels were statistically significant only for CCL2, 
CXCL8 and CXCL10 (Fig.3). These results indicate that cytokine-induced chemokine 
secretion was preferentially directed to the apical side of the endothelium.  
Chemokine receptor expression by cultured human brain endothelial cells
It is possible that chemokines released into the circulation act on brain endothelial cells in an 
autocrine manner or that receptors are involved in clearance of free chemokines from plasma. 
We therefore investigated the expression by cultured brain endothelial cells of the chemokine 
receptors to which the chemokines investigated above bind, namely CXCR1-3 and CCR1, 2 
and 5. Using semi-quantitative RT-PCR, primary HBEC expressed CCR1, CCR5 and 
CXCR1-3 mRNA but not CCR2 (Fig. 4a). At the protein level, CXCR1 and 3 were present at 
high levels, whereas levels of CXCR2 and CCR5 were lower and CCR1 and 2 were not 
detected by immunocytochemistry (Fig. 4b).  CXCR1 and CXCR3 appeared to be localised 
mainly intracellularly, in particular around the nucleus. The pattern of chemokine receptor 
expression did not differ between cells originating from MS brains and those obtained from 
epileptic patients (data not shown). 
The pattern of chemokine receptor expression of primary HBEC was similar to that observed 
in the hCMEC/D3 cell line, with CXCR1 and CXCR3 showing the highest levels of 
expression amongst the chemokine receptors tested (16). We therefore used this cell line to 
quantify changes in chemokine receptor expression induced by cytokines using FACScan 
analysis. Following incubation of hCMEC/D3 with TNF and IFN for 24 h, only CXCR3 
expression was significantly increased (p<0.05, n=3) whereas CCR1 expression was induced 
(p<0.05, n=3). No changes in expression were observed for CXCR1, CXCR2, CCR2 or
CCR5 (Fig. 5). 
Chemokine receptor expression by human brain endothelium in situ
Since CXCR1 and CXCR3 appeared to be expressed at high levels by cultured HBEC and 
CXCR3 was upregulated by cytokine stimulation, a detailed analysis of the expression of 
these two chemokine receptors by HBEC was performed in situ in MS brain sections. Active 
(CD68+, MHC class II+) and silent (CD68+, MHC class II -) lesions were compared with 
normal appearing white matter (NAWM) (CD68-, MHC class II-) in terms of expression of 
CXCR1 and CXCR3 by immunohistochemistry. In 50 m sections, double labelling with von 
Willebrand factor, an endothelial marker, and either CXCR1 or CXCR3 (Fig. 6a) revealed 
chemokine receptor staining associated with blood vessels in NAWM. In addition, other cells 
within the brain parenchyma which were negative for von Willebrand factor were also 
positively labelled for CXCR1 and CXCR3. Since human astrocytes have been previously 
shown to express CXCR1 and CXCR3 (29), double labelling with either CXCR1 or CXCR3 
and GFAP, a specific marker for astrocytes, was carried out to determine whether the positive 
chemokine receptor expression by blood vessels was due to associated astrocytic end-feet. A 
clear co-localisation of CXCR1 (Fig. 6b) and CXCR3 (not shown) with GFAP was observed 
in the astrocytic processes surrounding blood vessels. In addition, cells enclosed within the 
astrocytic end-feet were also positively labelled for CXCR1 (Fig. 6b) and CXCR3 (not
shown), although whether these cells were endothelial cells could not be ascertained. In MS 
lesions, CXCR1 (not shown) and CXCR3 (Fig. 6c) positive staining was diffuse throughout 
the lesion, probably due to astrogliosis and/or leukocyte infiltration.
Subcellular localisation of CXCR1 and CXCR3 by immunogold labelling and electron 
microscopy
To determine whether endothelial cells expressed chemokine receptors in situ, the 
immunogold technique using monoclonal antibodies to CXCR1 and CXCR3 was carried out 
on sections of MS brain tissue. Immunogold labelling with the monoclonal CXCR1 and 
CXCR3 antibodies revealed gold particles along the plasma membrane and cytoplasm of the 
endothelial cells, pericytes and astrocytic end-feet (Fig. 7a,b,d). Leukocytes, whether 
infiltrated or interacting with the endothelial cells on the luminal side, were also labelled for 
CXCR1 (Fig. 7c) and, to a lesser extent, CXCR3 (not shown). 
In the context of endothelial cells, labelling was easily identified at both the lumenal and 
ablumenal plasma membranes and within the cytoplasm of the capillary endothelial cells (Fig. 
7d). The total number of gold particles on endothelial cells per surface area for CXCR1 and 
CXCR3 did not vary significantly between NAWM, active lesions and silent lesions, with the 
exception of CXCR3 in silent lesions which was significantly lower than in NAWM or active 
lesions (Table 2). In NAWM, CXCR1 and CXCR3 antigenic sites were mainly localized at 
the cytoplasm, in particular for CXCR1 with approximately 87% of gold particles located in 
the cytoplasm compared to 65% for CXCR3 (Table 2). The distribution of antigenic sites 
between the lumenal and ablumenal membranes was different for CXCR1 and CXCR3, with 
a higher percentage of gold particles on the lumenal membrane compared to the ablumenal 
membrane for CXCR1, whereas the opposite was observed for CXCR3 (Table 2). The 
endothelial subcellular distribution of CXCR1 in MHC class II+ (active) and MHC class II-
(silent) lesions did not differ significantly from that observed in NAWM. By contrast, a 
significant reduction in CXCR3-immunolabelling on the lumenal membrane and a significant 
increase in CXCR3-immunolabelling within the cytoplasm was detected in MHC class II+
lesions (Table 2). Control experiments carried out to assess labelling specificity showed a 
negligible number of gold particles randomly distributed when the primary antibody was 
omitted.
Discussion
Acute inflammation in the CNS is characterised by inflammatory cell infiltrates, mainly
activated T helper cells and macrophages, but relatively few neutrophils. As chronic 
inflammation develops, activated T cells and macrophages are still prevalent, but resting 
CD4+ T cells and CD8+ T cells are present in increasing numbers. Many chemokines are 
strongly expressed in the CNS during multiple sclerosis [11]. However, it is thought that the 
set of chemokines which are expressed on the lumenal surface of the endothelium controls the 
pattern of leukocyte migration into each tissue including the CNS. Chemokines may be 
synthesised by the endothelium [19] or produced within tissues and transported across the 
endothelium in transport vesicles including caveolae [22, 26]. Transcytosis is more likely to 
be important in tissues such as the lung, where the bulk transport systems are well developed
[34]. Conversely, in the brain, where the endothelial barrier is strong and transcytosis limited, 
chemokine secretion by the endothelium itself is likely to be more important. Endothelia from 
different tissues vary in their chemokine secretion profiles and the rate of chemokine 
clearance from the cell surface [35]. Moreover, chemokine binding to the cell surface depends 
on the glycocalyx: brain microvascular endothelium has a particularly high negative charge, 
due to its sulphated gycosaminoglycans, which can interact with and retain positively-charged 
chemokines [36]. For these reasons, identifying chemokine production by brain endothelium 
is particularly important for understanding the distinctive patterns of leukocyte migration that 
occur in the CNS.
This study has shown that CCL2 and CXCL8 are produced and secreted by resting brain 
endothelium in vitro and by cerebral endothelium in normal-appearing brain tissue in situ. 
These chemokines, together with CXCL10 and CCL5 are induced following activation by 
inflammatory cytokines in endothelial cells in vitro, and in areas of inflammation and 
demyelination in MS tissue. Chemokine production by brain endothelium is indeed distinct 
from other endothelial subtypes, including primary microvascular endothelium from lung, 
dermis and liver and saphenous vein endothelium [19]. Our results are in agreement with 
previous reports demonstrating production of CCL2 and CXCL8 by HBEC isolated from 
temporal lobe of epileptic patients under resting conditions [37] and following stimulation 
with cytokines [38] or with supernatants derived from allogeneic or myelin basic protein 
reactive TH1 cells [39]. In this study, the chemokine profiles from primary brain endothelium
were similar, regardless of whether the cells came from MS patients or temporal lobe 
resection, and were broadly similar to the results with the cell line hCMEC/D3, suggesting 
that, in MS, HBEC do not show increased chemokine production per se but rather respond 
normally to the inflammatory environment they are exposed to by releasing chemokines. 
However, the level of production of CXCL8 and CXCL10 by brain endothelium is high by 
comparison with non-brain endothelia [19]. The finding with CXCL10 is notable, since this 
chemokine acts on CXCR3, which is strongly expressed on activated TH1 cells, precisely the 
population that is thought to drive the neuropathology of MS.
In contrast to other chemokines, CXCL8 secretion by HBEC was more variable either in 
resting or cytokine-stimulated cells. However, both EP and MS HBEC appeared to secrete 
variable levels of CXCL8 depending on the individual donor rather that on tissue type. This 
variability in CXCL8 expression has been observed by others in response to the HIV-1 
protein tat [40] and in endothelial cells from non-CNS tissues in response to cytokines [19]. It 
is possible that the number of cell divisions is a critical factor regulating the storage of 
CXCL8 in non-brain endothelial Weibel-Palade bodiescells, as previously demonstrated  [41].
The number of Weibel-palade bodies of cultured endothelial cells decrease as the number of 
passages increases [42]. In primary cultures, the number of cell divisions at the time of the 
assay could have varied between donors as the yield of capillary fragments and hence the 
number of cell divisions to attain confluence is dependent on a number of factors (post-
mortem time, quantity of tissue, cause of death, among others). Another possibility involves 
inter-individual variation amongst different donors. Indeed, CXCL8 plasma levels of healthy 
blood donors varied greatly in a recent study [4342] and variablity has also been 
demonstrated between different ethnic groups [4443].
The downregulatory effect of IFN and TGF on the TNF-induced upregulation of CXCL8 
secretion merits attention. Indeed, TGFis considered to be an anti-inflammatory cytokine 
and its expression has been detected in active MS lesions [4544]. However, CXCL8 inhibition 
by TGFwas only partial suggesting that it may not exert its anti-inflammatory effects in the 
presence of high levels of pro-inflammatory cytokines. The inhibitory effect of IFN on 
TNF-induced CXCL8 production has been reported in other cell types such as monocytes 
[4645]. The activation of NFB and AP-1 by TNF, required for CXCL8 transcription, is 
inhibited in the presence of IFN in endothelial cells [4746]. The suppression of CXCL8 
production by IFN may thus be considered a protective effect against CXCL-8 mediated 
neutrophil infiltration. Another important finding from the present study is that brain 
endothelium does not produce CCL3 in vitro. This is consistent with the observations in situ, 
which suggest that astrocytes, rather than endothelium are the main source of CCL3. These 
results stress the importance of correlating in vitro and in situ studies when investigating MS 
pathogenesis.
How does chemokine expression by HBEC relate to leukocyte infiltration? Apical release of 
chemokines by brain endothelium in vitro may rather reflect the rapid dilution of this 
chemokine by the blood stream in vivo. Indeed, chemokines released in the circulation would 
be rapidly degraded by proteases or their actions neutralized by decoy chemokine receptors 
such as DARC expressed by erythrocytes [4847]. Alternatively, chemokines released by 
endothelial cells may bind to the endothelial glycocalyx either on the secretory cell itself or 
on other endothelial cells further along the capillary wall trapping immune cells within the 
inflamed area either at the lumen or within the perivascular space. This may apply to 
CXCL10, as high levels of its receptor, which might serve to bind this chemokine, are 
detected on the abluminal side of brain endothelial cells in situ. Indeed, previous studies stress 
the importance of chemokines in directing leukocyte trafficking into the CNS. In chronic 
relapsing EAE in mice, disease severity correlated with CCL3 production during the initial 
acute phase, but more closely with CCL2 levels during relapse [4948]. These observations 
and the fact that CCL2-null mice do not develop EAE indicate a potential role for CCL2 in
the development of neuroinflammation [18]. Whether CCL2 is essential in EAE has however 
been questioned by other studies which show that EAE can develop in a number of CCR2-
deficienct mice [5049]. In this model  neuropathological examination showed a higher 
proportion of neutrophils and fewer macrophages than in normal animals, which suggests that 
macrophages can be partly replaced by neutrophils in producing the EAE pathology although 
it still implies that CCL2/CCR2 are important in monocyte migration into the CNS. In 
multiple sclerosis the levels of CCL3 in the CSF have a weak positive relationship to the level 
of cells present [5150] but this may merely reflect the fact that inflammation will activate 
astrocytes to produce CCL3, and does not necessarily imply that CCL3 is required to drive 
leukocyte transmigration. Indeed other evidence suggests that CCL2 is also important in 
controlling monocyte migration in MS and that migrating cells lose their CCR2 receptor as 
they transmigrate [10]. 
There is also considerable evidence that at least some endothelial-derived chemokines 
regulate leukocyte trafficking into the CNS, specifically of TH1 cells. Supernatants from 
TH1, but not TH2, cells induce production of CXCL10, CXCL8 and CCL2 by HBEC [39]. 
Using an in vitro human BBB model, Prat et al. [37] demonstrated that antibody 
neutralization of CCL2 considerably reduced migration of T lymphocytes isolated from MS 
patients across HBEC. Indeed, CCL2 has been shown to be crucial for the TH1 immune 
response in EAE [17]. These studies were expanded to show, using intravital microscopy, that 
treatment with anti-CCL2 or anti-CCL5 antibodies prevent leukocyte adhesion, but not 
rolling, in EAE [5251]. Our results have shown that brain endothelium itself is a major source 
of CCL2 as well as CXCL10, both of which have been implicated in the development of 
TH1-type inflammatory reactions in MS.
The expression of chemokine receptors on brain endothelium as determined by fluorescence 
microscopy and FACS analysis shows some similarity to other endothelia, with high 
expression of CXCR1 and CXCR3. Our findings are generally in agreement with Berger et al 
[28] who showed expression of CXCR1-3 by HBEC, although the expression of CXCR2 was 
low in the present study. In addition, we confirmed a low expression of CCR5 in agreement 
with other in vitro [28, 5352] and in situ [5453] studies. By contrast, although CCR2 
expression has previously been reported in HBEC [28], and more recently also in mouse BEC 
at the protein and mRNA level [5554], we could not demonstrate CCR2 expression either at 
the protein or transcript level in our study. Species differences in CCR2 expression cannot be 
ruled out at present. In the study of Berger et al [28], HBEC were positive by 
immunofluorescence using goat polyclonal antibodies to CCR2A but not with those to 
CCR2B, whereas we used a more specific CCR2 monoclonal antibody. In addition, 
Andjelkovic et al [5352] showed binding sites to CCL2 in isolated human brain capillaries, 
although this may either be due to other cell types expressing CCR2 such as perivascular 
cells/pericytes, or to other endothelial chemokine receptors (i.e. DARC).
The function of endothelial chemokine receptors has not been defined. Interestingly, CXCR1 
and CXCR3 bind to CXCL8 and CXCL10 respectively, which would allow secreted 
chemokines to act in an autocrine fashion. Previous studies have suggested that signalling via 
CXCR1 is angiogenic, whereas signalling via CXCR3 is angiostatic [27]. Another potential 
function for endothelial chemokine receptors is to clear the plasma of free chemokines, so that 
leukocytes do not become activated unless they are triggered by chemokines held on the 
endothelial glycocalyx. Finally, it has been proposed that chemokine receptors could be 
involved in transport of chemokines across endothelium. Our observation that the subcellular 
localization of CXCR3 is altered in MS lesions compared to NAWM is suggestive of this 
hypothesis. Indeed, there appears to be an increase in the intracellular pool of CXCR3, and a 
decrease in the ablumenal membrane in MS lesions. The fact that CXCL10 induces the 
internalisation of its receptor [5655] might account for the observed increase in the 
intracellular pool of CXCR3 as CXCL10 is increased in MS lesions and could explain the 
decrease of the receptor on the ablumenal side. CCR2 has been suggested to act as a means of 
transport for its chemokine ligand, CCL2 across the BBB [5756]. It is possible that the same 
case applies for CXCR3 and its ligand, as they are greatly increased in the lesions, mainly in 
the active lesions. Indeed, we have shown that CXCR3 is upregulated by cytokine treatment 
in a human brain endothelial cell line. However, our in vitro results should be approached 
with caution as hCMEC/D3 cells do no retain all characteristics of the BBB phenotype, such 
as high transendothelial resistance [20], and the pattern of chemokine expression was 
somewhat different between primary HBEC and the immortalised cell line. Whether this is 
the case forCXCR3 transports CXCL10 across human brain endothelium remains to be 
determined. 
This study has shown that human brain endothelium cultured in vitro expresses a similar 
pattern of chemokines and chemokine receptors to that seen in situ. It has shown that brain 
endothelium responds to cytokine stimulation by secreting chemokines, and does so with the 
same response pattern as other microvascular endothelium. However it also highlights the 
high secretion of CXCL8 and CXCL10, in comparison with other endothelia, which may
explain the distinctive TH1-pattern of chronic inflammation in the brain, seen in diseases such 
as MS. 
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Figure legends
Fig. 1: Chemokine expression in multiple sclerosis brain tissue 
Representative photographs taken from sections of the frontal lobe of cases with MS (Table 
1) immunolabelled to detect CCL2, CCL5, CXCL8 or CXCL10 .  [A, A', A'', H]: paraffin-
embedded sections at 3m thickness. [B-G, I]: frozen sections cut at 20m thickness [A, A', 
A'',B, H] are taken from non-demyelinated areas. [C-G, I] are taken from demyelinating 
plaque areas.  [A'] and [A''] represent high power photographs of endothelial cells expressing 
CCL2 from the same case as shown in [A].  [A' and A''] show higher power photographs of 
endothelial cells expressing CCL2. Polarised expression is indicated by an arrowhead in [A']. 
The (unlabelled) nucleus of an endothelial cell is indicated by the adjacent (e) in [A'']. The 
asterisk in [B] denotes a perivascular cell expressing CCL2, associated with the external 
(parenchymal) blood vessel wall. The scale bar represents approx. 115m in [A], 20m in 
[A', A''], 195m in [B], 410m in [C], 150m in [D], 95m in [E,F], 85m in [G], 100m in 
[H] and 335m in [I]. Nuclei have not been counterstained.
Fig. 2: Chemokine release into culture medium by primary HBEC and the hCMEC/D3 
cell line under basal conditions and following stimulation by cytokines for 48 h.
Supernatants from confluent monolayers of HBEC or hCMEC/D3 cells were collected after 
48 h stimulation with TNF (50 ng/ml), IFN (100 ng/ml) and TGF (25 ng/ml) or a 
combination of them and assayed by sandwich ELISA for (a) CXCL8 (b) CXCL10 (c) CCL2 
and (d) CCL5. Results presented are means ± S.E.M. of 3-5 different experiments for HBEC 
isolated from MS brain tissue (white), 3 for HBEC isolated from temporal lobe resections 
from epileptic patients (grey) and 3 for the hCMEC/D3 cell line (black) with duplicate wells. 
Significant differences were determined by ANOVA followed by a post hoc t-test for CCL2, 
CCL5 and CXCL10 and by a Kruskal-Wallis and Mann-Whitney test for CXCL8. * 
significant difference (p<0.05) versus the control; Δ significant difference (p<0.05) of sample 
treated with a combination of cytokines versus TNF- treated sample;  significant difference 
(p<0.05) of sample treated with a combination of cytokines versus IFN treated sample.
Fig 3: Chemokine release into the apical and baso-lateral culture medium by primary 
HBEC grown on filters under basal conditions and following stimulation by cytokines. 
Supernatants from confluent monolayers of human brain endothelial cells grown on filters 
were collected at 48 h from both the apical (white) and the basolateral sides (grey) and 
assayed by sandwich ELISA for CXCL8, CXCL10, CCL2, and CCL5. Results presented are 
means ± S.D. from two different experiments with duplicate wells. Significant differences 
were determined by ANOVA followed by a post hoc t-test. * significant difference (p<0.05) 
versus the control;  significant difference (p<0.05) between concentration at the apical 
chamber and the basal chamber.
Fig. 4. Chemokine receptor expression by primary HBEC detected by (a) semi-
quantitative RT-PCR and (b) immunocytochemistry. cDNA for CCR1, CCR5, CXCR1, 
CXCR2 and CXCR3 was detected in primary HBEC but not that of CCR2 (+). Cyclophilin 
was used as positive control and to ensure equal cDNA loading for each sample. Negative 
controls (-) of samples incubated in the absence of RT were included. Results are 
representative of 2 experiments. (b) Immunofluorescence staining of primary HBEC for 
CCR5, CXCR1, CXCR2 and CXCR3 (Texas red; bottom). CXCR1 and CXCR3 showed a 
predominant surface staining extending over the cell body. CXCR2 and CCR5 showed 
predominantly vesicle staining. Scalebar = 20 m.
Fig. 5. Chemokine receptor expression by hCMEC/D3 cells under basal conditions and 
following stimulation by cytokines for 24 h.  (a) Representative FACScan histograms show 
the expression of unstimulated hCMEC/D3 cells (black line) and hCMEC/D3 cells stimulated 
with 500ng/ml TNFα and 10ng/ml IFN for 24 h (grey line). hCMEC/D3 cells were fixed 
with 4% PAF, permeabilised with triton X-100, labelled with FITC- or PE- labelled 
antibodies specific for CXCR1, CXCR2, CXCR3, CCR1, CCR2 and CCR5, and analysed by 
FAScan. Cells labelled with FITC- or PE- labelled isotope-matched antibodies are 
represented as grey filled histograms. The histograms are of one experiment representative of 
three. (b) Results are expressed as the mean fluorescence for chemokine receptor expression 
by unstimulated hCMEC/D3 cells (white) and hCMEC/D3 cells stimulated with 500ng/ml 
TNFα and 10ng/ml IFNγ (grey) for 24 h. Control values have been subtracted. Significance 
was tested on normalised values by ANOVA with a post hoc t-test (* p<0.05). Results 
presented are the mean ± S.E.M. of three different experiments. 
Fig. 6. Immunofluorescent detection of CXCR1 and CXCR3 in human NAWM and MS 
lesions. Fixed 50 m thick sections cut with a vibratome were permeabilised with triton X-
100 and then processed for detection of either CXCR1 (b) or CXCR3 (a, c) (in red) and either 
von Willebrand factor (a), an endothelial cell marker, or GFAP (b,c), an astrocyte marker, (in 
green) by immunohistochemistry in NAWM (a, b) and in a chronic active MS lesion (c). 
Merged images show the localisation of CXCR1 and CXCR3 within the neurovascular unit. 
Results are representative of experiments from six donors. Scale bar= 40 m
Fig. 7. Electron micrographs of CXCR1 and CXCR3-labelled MS brain tissue. Fixed 50 
m thick sections were processed for detection of CXCR1 and CXCR3 using silver-enhanced 
gold particles and visualized by electron microscopy. (A) Brain capillary endothelial cells and 
the perivascular end-feet of astrocytes show CXCR1-antigenic sites positively labelled with 
gold particles in NAWM. (B) In a chronic active lesion (MHC class II +), both brain capillary 
endothelial cells and pericytes are labelled for CXCR1. Inset represents dashed area at higher
magnification showing positive immunogold labelling for CXCR1 on the lumenal surface of 
brain endothelial cells. (C) Leukocytes interacting with brain endothelial cells within the 
lumen (asterisk) are highly positive for CXCR1 in a chronic active lesion (MHC class II +). 
(D) In a silent lesion, CXCR3 is distributed mainly within the cytoplasm of endothelial cells 
(some within endosomes) but also on the lumenal (asterisk) and ablumenal membranes. 
Abbreviations: AE=astrocytic end-feet; EC= endothelial cell; E= erythrocyte; L=leukocyte; 
P=pericyte. Scale bar= 1 m
Figures Printed Black / White - No Publication Charges
CCL5
0
10
20
30
40
50
60
70
B
a
s
a
l
IF
N
T
N
F
T
G
F
IF
N
+
T
N
F
IF
N
+
T
G
F
T
N
F
+
T
G
F
n
g
/m
l
MS HBEC
Ep HBEC
hCMEC/D3
CXCL8
0
100
200
300
400
500
B
a
s
a
l
IF
N
T
N
F
T
G
F
IF
N
+
T
N
F
IF
N
+
T
G
F
T
N
F
+
T
G
F
n
g
/m
l
MS HBEC
Ep HBEC
hCMEC/D3
CXCL10
0
100
200
300
400
500
B
a
s
a
l
IF
N
T
N
F
T
G
F
IF
N
+
T
N
F
IF
N
+
T
G
F
T
N
F
+
T
G
F
n
g
/m
l
MS HBEC
Ep HBEC
hCMEC/D3
*
*
*
*
*
*
Δ
Δ
Δ
*
Δ
Δ
Δ
*
*
*
*
*
* *
*
CCL2
0
10
20
30
40
50
60
B
a
s
a
l
IF
N
T
N
F
T
G
F
IF
N
+
T
N
F
IF
N
+
T
G
F
T
N
F
+
T
G
F
n
g
/m
l
MS HBEC
Ep HBEC
hCMEC/D3
*
*
*
*
*
Δ
Δ
Δ**
* *
*
*
*
*
*
*
*
*
*
•
•
B
a
s
a
l
IF
N
T
N
F
T
G
F
IF
N
+
T
N
F
IF
N
+
T
G
F
T
N
F
+
T
G
F
n
g
/m
l
B
a
s
a
l
IF
N
T
N
F
T
G
F
IF
N
+
T
N
F
IF
N
+
T
G
F
T
N
F
+
T
G
F
n
g
/m
l
B
a
s
a
l
IF
N
T
N
F
T
G
F
IF
N
+
T
N
F
IF
N
+
T
G
F
T
N
F
+
T
G
F
n
g
/m
l
B
a
s
a
l
IF
N
T
N
F
T
G
F
IF
N
+
T
N
F
IF
N
+
T
G
F
T
N
F
+
T
G
F
n
g
/m
l
B
a
s
a
l
IF
N
T
N
F
T
G
F
IF
N
+
T
N
F
IF
N
+
T
G
F
T
N
F
+
T
G
F
n
g
/m
l
Figures Printed Black / White - No Publication Charges
0100
200
300
400
500
C
I+
T C
I+
T
c
h
e
m
o
k
in
e
 (
n
g
/m
l)
Apical
Basal
CXCL8 CXCL10
0
10
20
30
C
I+
T C
I+
T
C
h
e
m
o
k
in
e
 (
n
g
/m
l)
Apical
Basal
CCL2 CCL5
*
•
*
•
*
*
•
*
*
C
I+
T C
I+
T
c
h
e
m
o
k
in
e
 (
n
g
/m
l)
C
I+
T C
I+
T
C
h
e
m
o
k
in
e
 (
n
g
/m
l)
C
I+
T C
I+
T
c
h
e
m
o
k
in
e
 (
n
g
/m
l)
C
I+
T C
I+
T
C
h
e
m
o
k
in
e
 (
n
g
/m
l)
Figures Printed Black / White - No Publication Charges
- +
(a)
(b)
vWFvWF vWF
CXCR3CXCR1CCR5
vwf
cxcr2
CXCR2
vWF
RT
cycloph
- +
CCR1
- +
CCR2
- +
CCR5
- +
CXCR1
- +
CXCR2
- +
CXCR3
- +
550 bp
240 bp
519 bp
230 bp
496 bp 477 bp
200 bp
Figures Printed Black / White - No Publication Charges
100 101 102 103 104
CXCR1 (FL-1)
0
1
2
8
E
v
e
n
ts
CXCR1
100 101 102 103 104
CXCR3 (FL-2)
0
1
2
8
E
v
e
n
ts
CXCR3
100 101 102 103 104
CXCR2 (FL-2)
0
1
2
8
E
v
e
n
ts
CXCR2
100 101 102 103 104
CCR5 (FL-1)
0
1
2
8
E
v
e
n
ts
CCR5
100 101 102 103 104
CCR2 (FL-2)
0
1
2
8
E
v
e
n
ts
CCR2
100 101 102 103 104
CCR1 (FL-2)
0
1
2
8
E
v
e
n
ts
CCR1
(a)
(b)
0
20
40
60
80
100
120
140
CXCR1 CXCR2 CXCR3 CCR1 CCR2 CCR5
Chemokine Receptors
A
rb
it
ra
ry
 U
n
it
s
Basal
IFN+TNF
*
*
0
1
2
8
E
v
e
n
ts
0
1
2
8
E
v
e
n
ts
0
1
2
8
E
v
e
n
ts
0
1
2
8
E
v
e
n
ts
0
1
2
8
E
v
e
n
ts
0
1
2
8
E
v
e
n
ts
A
rb
it
ra
ry
 U
n
it
s
Figures Printed Black / White - No Publication Charges
AC
B
Color Figure - Agree to Pay Publication Charges
AEC
AE
D
EC
E
*
*
C
L
L
EC
E
E
*
B
EC
E
P
*
Figures Printed Black / White - No Publication Charges
Case Age 
(years)
Gender Postmortem 
delay (h)
Cause of death Lesion 
activity
Source
1†‡ 34 Female 15 Pneumonia Active and 
silent lesions
MSTB
2†‡ 44 Female 36 Multiple sclerosis Active and 
silent lesions
MSTB
3†‡ 50 Female 13 Multiple sclerosis Chronic 
active lesions
MSTB
4* 53 Male <30 Septicaemia due to 
upper respiratory 
tract infection, 
multiple sclerosis 
n.d. MSTB
5*† 59 Female 32 Respiratory failure, 
cardiac arrest
NAWM MSTB
6* 59 Female <30 Pneumonia n.d. MSTB
7*† 70 Female 21 Aspiration 
pneumonia, sepsis, 
multiple sclerosis
Silent lesions MSTB
8† 71 Female 36 Bronchopneumonia, 
multiple sclerosis
NAWM MSTB
9* 92 Male <30 “Old age” n.d. MSTB
10† 34 Female 32 Paracetamol 
overdose
Silent lesions LBBND
11† 47 Male 7 Bilateral 
bronchopneumonia
Chronic 
active lesions
LBBND
12† 54 Female 32 Pulmonary embolus Active and 
silent lesions
LBBND
13† 56 Female 6 Chronic MS Silent lesions LBBND
Table 1.  Demographic details of cases diagnosed with multiple sclerosis, from 
which brain tissue was obtained. (MSTB) UK Multiple Sclerosis Tissue Bank; 
(LBBND) MRC London Brain Bank for Neurodegenerative Diseases; (n.d.) indicates 
‘not determined’; (NAWM) indicates ‘normal appearing white matter’; (*) denotes
cases from which tissue was used for primary culture of HBEC; (†) denotes cases 
from which tissue was used for immunohistochemical and immunofluorescence 
studies; (‡) denotes cases from which tissue was used for immuno-EM studies.
Table
Table 2. Distribution of CXCR1 and CXCR3 antigenic sites in human brain capillary 
endothelial cells in situ#
#corresponding to 16-19 capillaries from three cases for each tissue type. 
*P<0.05 compared to NAWM. Results represent the mean ± S.E.M.
NAWM Active Lesion 
(MHC class II +)
Silent Lesion
(MHC class II -)
CXCR1 CXCR3 CXCR1 CXCR3 CXCR1 CXCR3
No. gold particles/m² 0.63±0.13 0.79±0.22 0.54±0.13 0.84±0.22 0.56±0.14 0.32±0.06*
Luminal membrane (%) 8.9±1.9 14.5±4.1 9.8±2.7 16.5±6.8 19.7±7.9 12.3±4.3
Abluminal membrane (%) 3.6±1.9 20.6±6.4 3.6±1.7 4.5±1.9* 6.6±2.4 17.8±6.9
Cytoplasm (%) 87.4±2.8 64.9±7.4 86.6±3.8 79.0±6.9* 73.7±7.9 69.9±7.3
Formatted Table
Table
NAWM
Active lesion
(centre)
Suppl. Fig. 1: Immunohistochemical detection of CD68 or MHC class II in NAWM and in MS active, chronic 
active and silent lesions counter stained with hematoxylin. 
Fixed 50 mm thick sections cut with a vibratome were permeabilised with triton X-100 and then processed for detection 
of CD68 or MHC class II by immunohistochemistry. Sections were then counterstained with haematoxylin to visualise 
cell nuclei in NAWM and in MS lesions. Scale bar=50 mm
Chronic active lesion
(centre)
Chronic active lesion
(edge)
Silent lesion
(centre)
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